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Abstract 
The number of people in the modern world being affected by allergic diseases and 
asthma has reached epidemic proportions. With over 1 out of three people requiring 
some sort of treatment for allergic disease, the burden placed onto industrialized 
nations healthcare systems is increasing. Mild forms of allergic diseases, such as 
allergic rhinitis, can be treated with anti-histamines or immunological desensitization. 
However, more severe forms of disease, such as asthma and atopic dermatitis, 
require a reduction of systemic inflammation by administration of broad acting 
systemic immunosuppressants, to effectively alleviate symptoms. However, systemic 
immunosuppression often results in susceptibility to infection.  
Mast cells, which are evidently involved in numerous allergic pathologies, have not 
been adequately targeted by conventional therapeutics. Specific removal of mast 
cells, by means of antibody-dependent depletion, would interrupt the allergic cascade 
and might yield significant benefit for patients. In order to develop such a mAb-
mediated mast cell ablation approach we sought to established proof of principle in a 
well-controlled system with our newly developed transgenic mouse model. The 
Cpa3hCD4 mouse model expresses a truncated human CD4 receptor from a knockin 
into the mast cell specific Cpa3 locus. With this model system, employing an artificial 
mast cell marker cell surface protein, we could show that several tissue-resident 
mast cell compartments can be safely and efficiently depleted after intravenous α-
hCD4 administration. To identify a physiologically relevant target on the surface of 
mast cells, we underwent extensive mass spectrometry-assisted proteomic profiling 
of primary mouse and human mast cells. Analysis of the data revealed a cross-
species conserved mast cell protein signature, among which we found several 
drugable receptors. Quantitative analysis, paired with flow cytometry-based 
verification of the cell surface expressed mast cell proteins allowed us to identify 
several highly expressed mast cell specific cell surface markers. Targeting of one of 
these receptors with an α-CD63-Immunotoxin resulted in the efficient depletion of 
mast cells in vitro. In vivo however, efficacy of mast cell depletion was limited by 
excessive on-target toxicities. Along these lines, we are currently evaluating the 
herein identified physiological mast cell targets for cellular depletion by different 
antibody-mediated mechanisms. 
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Zusammenfassung 
 
In den Industrienationen nimmt die Anzahl der Menschen, die von allergischen 
Erkrankungen und Asthma betroffen sind, stetig zu und hat vielerorts bereits 
epidemische Ausmaße erreicht. Milde Formen von allergischen Erkrankungen, wie 
allergische Rhinitis, können mit Anti-Histaminika oder immunologischer 
desensitizierung behandelt werden. Ernsthaftere Krankheitsformen, wie z.B. Asthma 
oder atopische Dermatitis, erfordern allerdings die Verabreichung von breit 
wirkenden Immunsuppressiva, um die Symptome wirksam zu lindern. Solche 
systemisch verabreichten Immunsuppressiva führen oftmals zu pleiotropen 
Wirkungen wie z.B. erthöhter Infektionsanfälligkeit. 
Mastzellen, die erwiesenermaßen in zahlreichen allergischen Krankheiten eine 
zentrale Rolle spielen, werden durch konventionelle Therapeutika nicht adäquat 
adressiert. Die spezifische Entfernung von Mastzellen, mittels Antikörper-abhängiger 
Zell ablation, würde die allergische Kaskade unterbrechen und für Patienten 
signifikante Vorteile bringen. Um einen solchen Mastzell-Ablationsansatz zu 
entwickeln, haben wir ein transgenes Mausmodell entwickelt, welches auf der 
ektopen Expression eines human-CD4-Rezeptors aus dem Mastzell-spezifischen 
Gen Cpa3 basiert. Mit diesem Modellsystem, und dem artifiziellen Mastzell 
Oberflächenprotein, konnten wir zeigen, dass nach intravenöser Verabreichung von 
α-hCD4 Antikörpern mehrere Gewebs-ständige Mastzell Populationen effizient und 
gefahrlos ablatiert werden können. Um ein physiologisch relevantes 
Oberflächenprotein auf Mastzellen zu identifizieren, haben wir umfangreiche 
massenspektrometrisch-gestützte Proteom Untersuchungen von primären murinen- 
und menschlichen Mastzellen durchgeführt. Basierend auf den Daten konnten wir 
nicht nur mehrere Mastzell-spezifische Oberflächenziele identifizieren, sondern auch 
eine evolutionär erhaltene Mastzell-Protein Signatur entdecken.  
Die Behandlung von Mastzellen, mit einem α-CD63-Immunotoxin, führte zu einer 
effizienten Ablation von Mastzellen in vitro. In vivo wurde jedoch die Wirksamkeit der 
Mastzellablation durch die auftretenden Nebenwirkungen limitiert. Zurzeit, evaluieren 
wir die hier identifizierten physiologischen Mastzell-Zielantigene für die zelluläre 
Ablation mit Hilfe verschiedener Antikörper-vermittelter Ablationsmechanismen.  
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1. Introduction 
1.1. Discovery of mast cells 
Paul Ehrlich first described mast cells in the late 19th century. When he stained 
connective tissue sections with aniline dyes, he observed granulated cells that 
exhibited metachromatic staining properties. The basic dyes he used (e.g. toluidine 
blue) stain the cells blue, however the acidic glycosaminoglycan residues within the 
mast cell granules react with the dye resulting in a characteristic colour change from 
blue to purple (metachromasia). The metachromatic staining properties of mast cells 
allowed the specific detection of the cells in tissues (Ehrlich, 1878). Due to their vast 
amount of intracellular granules he thought that the cells had a nourishing function to 
the surrounding tissue, and thus termed them “Mastzelle” which derives from the 
German word for “mästen” (fattening).  
1.2. Phylogeny and lineage development 
Mast cell-like cells are evolutionary ancient and have been described in the 
haemolymph of the ascidian Styela plicata, which belongs to the group of 
invertebrate chordates (urochordates), that first appeared over 500 million years ago 
(Cavalcante et al., 2002; de Barros et al., 2007). The so-called “test-cells”, that are 
associated with the ascidians’ oocytes, possess intracellular heparin positive 
granules and release histamine and tryptases after exposure to compound 48/80, a 
potent liberating compound of mammalian mast cells. The authors proposed that test 
cells protect the oocyte against microbial infections (Cavalcante et al., 2002). In 
osteichthyes that first appeared 420 million years ago, a primitive form of an 
activating Fc receptor (FcR) and the tyrosine receptor kinase Kit (CD117) could be 
identified on mast cells. However, the expression of the high-affinity receptor for IgE 
(FcεRI) and other activating FcRs on mast cells was not acquired until the evolution 
of mammals 225 million years ago (Voehringer, 2013). 
 
Mast cells belong to the hematopoietic system and, like the other immune cells in 
mice and humans, they develop from hematopoietic stem cells residing in the bone 
marrow (Kitamura et al., 1977). Mature mast cells are only found in peripheral tissues 
mainly at the bodies’ interface to the environment, not in bone marrow or blood. The 
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fate and interrelationship of intermediary progenitors of the mast cell lineage are still 
under debate. Common consensus however is, that immature mast cell-committed 
progenitors (MCP) travel via the blood stream and migrate into tissues where they 
complete their tissue specific maturation (Gurish and Austen, 2012; Yojiro Arinobu, 
2005). During embryonic development the earliest committed progenitor for mast 
cells was identified in murine foetal blood at day 15.5 of gestation (Rodewald et al., 
1996). The occurrence of committed MCP declines with age, and in adult mice the 
frequency of MCPs is approximately 0.0045% of blood mononuclear cells (Dahlin et 
al., 2013).  Such a low frequency suggests either self-renewing capacity or rapid 
migration of progenitors into the tissues; the degree of each would depend on the 
resident MC turnover rates. 
An increase of the progenitor population is observed under specific inflammatory 
conditions, such as nematode infection or allergic lung inflammation. Under these 
conditions a sequential increase of MCPs first in the bone marrow, then in the blood 
and finally in the intestine or lung could be observed (Bankova et al., 2015; Pennock 
and Grencis, 2004). 
Mature mast cells are categorized into two subtypes according to their tissue 
localization and their granule content: mucosal mast cells (MMC), and connective 
tissue resident mast cells (CTMC).  
 
 
Figure 1: Functional and phenotypic differences between mast cell populations 
Murine and human MC can be categorized into populations defined by anatomical 
location and/or granule content (proteoglycans (heparin or chondroitin sulfates) and 
proteases (tryptases, chymases or Cpa3). Figure was adapted from (Galli et al., 
2011). 
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MMC differ from their CTMC counterparts in terms of anatomical location, staining 
characteristics, radiation sensitivity and T cell dependence for development (Fig. 1) 
(Galli et al., 2011; Gurish and Austen, 2012). CTMCs are predominantly located in 
the subepithelial layers of the skin and within the peritoneal cavity, as well as within 
the submucosal layers of the intestine. Their granules are storage compartments for 
different kind of mediators and proteases, most typical chymase, tryptases and mast 
cell carboxypeptidase A (Cpa3). These enzymes are complexed to proteoglycans. 
The glycosaminoglycan (GAG) side chains most characteristic for CTMC are heparin. 
In contrast, MMCs, predominantly locate to epithelial layers in the intestinal and 
respiratory tract. They are smaller in size than CTMC and contain fewer granules. 
The granules of MMC preferentially contain chondroitin sulphate GAG side chains. 
They contain chymase, but no tryptase (Metcalfe et al., 1997). In contrast to the pool 
of CTMCs which are constitutively present, MMC are T cell dependent and mainly 
expand during inflammatory conditions from bone marrow derived MCPs (Gurish and 
Austen, 2012). Within three weeks after resolution of inflammation, MMC decrease 
again by number, suggesting a relatively short life span. CTMC on the contrary, have 
been postulated to have an extraordinary long life span of more than one year in 
mice (Kitamura, 1989). 
  
Human MCs may also be classified into two subsets, based on their content of serine 
proteases within their granules. MCs that harbour tryptase-only granules are 
designated as MCT whereas MCTC are positive for tryptase and chymase (Moon et 
al., 2009). MCT resemble the murine MMC whereas MCTC are the counterparts to 
CTMC. While human lungs and intestinal mucosa mostly contain MCT, MCTC are the 
predominant subtype found in connective tissues such as skin and fat. However, it 
has been reported that under chronic inflammation, such as asthma, human lung 
mast cells can acquire a MCTC phenotype (Erjefalt, 2014). 
1.3. Mast cells in health and disease 
Roughly 30 years after Paul Ehrlich discovered the mast cells, Clemens von Pirquet 
described patients who showed signs of hypersensitivity reaction to secondary 
immunization with smallpox. Based on these observations he proposed the concept 
of allergy as an immunological hypersensitivity reaction (Pirquet, 1906). In 1937 a 
link between mast cells and heparin was suggested upon observing that tissues 
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containing high mast cell numbers were enriched in heparin (Holmgren and Wilander, 
1937). In 1947 it was shown that during anaphylactic shock histamine and heparin 
were liberated and subsequently it was formally shown that mast cells not only 
contain heparin but also histamine (Riley and West, 1953; Rocha e Silva and 
Scroggie, 1947), and may be activated by the polymeric basic secretagogue 
compound 48/80 to induce anaphylaxis (Mota and Vugman, 1956; Riley and West, 
1955). However, not until the discovery of IgE in 1966, the molecular resolution of the 
complete FcεRI (1989) and its expression on mast cells, a clear cellular and 
molecular link between MC, allergen and type 1 hypersensitivity reactions could be 
drawn (Blank et al., 1989; Ishizaka and Ishizaka, 1966). 
 
In order for mast cells to elicit a hypersensitivity reaction, allergen sensitization must 
occur prior to exposure. Allergen sensitization may take place at body surfaces that 
provide barriers to the environment e.g. lung, skin or intestine. Whether an Individual 
becomes sensitized to a certain allergen depends on genetic and environmental 
factors (Tsai et al., 2008), and remains incompletely understood. 
In case of the allergen sensitization in the lung, innocuous allergens are inhaled and 
deposited in the airway lumen. Activated dendritic cells sample the allergen and 
migrate to the draining lymph nodes where they encounter allergen-specific naïve T 
cells. With signalling downstream of IL-4, the T cells differentiate along the TH2 
pathway. Allergen-specific TH2 cells then provide help to B cells in the germinal 
centers of draining lymph nodes to induce antibody generation and class switching to 
IgE. Allergen specific IgE antibodies are produced, bind to mast cells and preactivate 
them (sensitization). Upon re-exposure to allergen mast cells become activated and 
degranulate for immediate mediator release.  
Introduction 
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Figure 2.: Sensitization to allergens in the airways 
Allergen inhalation results in activation of the immune system and generation of 
allergen specific IgE antibodies that may arm and subsequently activate mast cells. 
Adapted from (Tsai et al., 2008). 
 
Apart from histamine and heparin, mast cell activation may result in the release of a 
wide array of bioactive substances (Wernersson and Pejler, 2014). Depending on the 
nature of stimulus three distinct classes of mediators are released: preformed 
mediators, stored in secretory granules; lipid mediators, derived from arachidonic 
acid; and newly synthesized mediators, which are produced following transcriptional 
activation (Marshall, 2004). An overview of mast cell derived mediators is presented 
in table 1. 
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 Mediators Example of function 
G
ra
nu
la
r 
Histamine and 5-
Hydroxytryptamine (Serotonin) 
Promotes DC migration, suppresses T cell mediated adaptive 
immune responses, causes vasodilation, promotes angiogenesis, 
induces pain and itch 
Heparin and chondroitin 
sulphate peptidoglycans Enhance chemokine and/or cytokine function and angiogenesis 
Tryptase, chymase, Cpa3 and 
other proteases Tissue remodelling and recruitment of effector cells 
TNF-α, VEGF and FGF2 Recruit effector cells and enhance angiogenesis 
Li
pi
d-
de
riv
ed
 
LTC4, LTB4, PGD2 and PGE2 
Recruit effector cells, regulate immune responses and promote 
angiogenesis, oedema and bronchoconstriction 
Platelet-activating factor Activates effector cells, enhances angiogenesis and induces physiological inflammation 
C
yt
ok
in
es
 
TNF-α, IL-1α/β, IL-6 
Promotes recruitment of innate immune cells (i.e. neutrophils), 
enhances protective antigen-specific antibody dependent immune 
response 
IL-4, IL-5, IL-13 Promotes TH2 immune response  
IL-12, IFN-γ Promotes TH1 immune response  
IL-10, TGF-β 
Suppresses adaptive immunity, promotes peripheral tolerance to 
skin allograft, suppresses innate immune response to chronic UVB 
radiation exposure 
VEGF and FGF2 Angiogenesis 
G
ro
w
th
 
fa
ct
or
s 
SCF, GM-CSF, GnRH-1, b-FGF, 
NGF, VEGF 
Promote mast cell development, differentiation, maturation and 
proliferation 
C
he
m
ok
in
es
 
CCL2, CCL3, CCL4, CCL5, 
CCL11and CCL20 
Recruit effector immune cells (i.e. neutrophils, monocytes and 
dendritic cells) 
CXCL1, CXCL2, CXCL8, 
CXCL9, CXCL10 and CXCL11 Recruit immune cells and regulate immune response 
O
th
er
 Nitric oxide and superoxide 
anions Bactericidal 
Antimicrobial peptides Bactericidal 
Table 1: Mediators released from activated mast cells  
CCL, CC-chemokine ligand; CXCL, CXC-chemokine ligand; FGF2, fibroblast growth 
factor 2; GM-CSF, granulocyte/macrophage colony-stimulating factor; IFN, interferon; 
IL, interleukin; LIF, leukaemia inhibitory factor; LT, leukotriene; PG, prostaglandin; 
TGF-β, transforming growth factor-β; TNF, tumour-necrosis factor; VEGF, vascular 
endothelial growth factor (Kumar and Sharma, 2010; Marshall, 2004). 
 
Mast cells are strategically located in tissues facing the environment and in close 
proximity to blood vessels, lymphatic vessels and nerve fibres (Krystel-Whittemore et 
al., 2015; Kumar and Sharma, 2010). Their location within sites of frequent microbial 
exposure suggests a sentinel function of mast cells in host defence. In that regard, 
mast cells can release potent vasodilators such as histamine and serotonin and are 
able to recruit immune cells by secretion of chemokines and cytokines (Table 1) 
(Marshall, 2004). Consistent with this idea, mast cells have been shown to express a 
wide array of cell surface receptors that allow for recognition and detection of noxious 
substances and pathogens (Kumar and Sharma, 2010). Among these are toll-like 
receptors (TLRs), of which functional expression of TLR1, TLR2, TLR3, TLR4, TLR6, 
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TLR7 and TLR9 has been described for murine mast cells (Sandig and Bulfone-
Paus, 2012). However, almost all of these studies were performed with in-vitro 
differentiated mast cells from various sources and thus have to be confirmed on 
primary mast cells before conclusions about potential functions may be drawn. 
Similarly, TLR mRNA expression in human primary mast cells has been described, 
however verification of TLR protein is still missing (Sandig and Bulfone-Paus, 2012). 
Receptors other than TLRs that can be found on mast cells are Fcγ-receptors 
(Tkaczyk et al., 2004), complement receptors (Johnson et al., 1975), cytokine and 
chemokine receptors (Marshall, 2004). The latter might sense local inflammation and 
induce mast cell activation independent of IgE. 
Functional studies on TLR activation in cultured mast cells revealed selective 
production of inflammatory cytokines and chemokines (Matsushima et al., 2004; 
Supajatura et al., 2002). A potential function that is largely overlapping with other 
tissue resident immune cells, such as macrophages and dendritic cells (Galli et al., 
2011). 
In order to test in vivo mast cell functions researchers have traditionally relied on Kit 
mutant mice. KitW/Wv mice carry a spontaneous loss-of-function mutation in both Kit 
alleles and were the first Kit mutant strain described to be mast cell deficient 
(Kitamura et al., 1978). Because Kit expression is not restricted to mast cells and 
SCF signalling is crucial for various other cell types within and outside of the 
hematopoietic system, these mice carry many abnormalities apart from their mast 
cell deficiency (Nigrovic et al., 2008; Rodewald and Feyerabend, 2012). 
Based on experiments performed with these mouse strains, mast cells have been 
erroneously regarded as masters of the immune system with a widespread spectrum 
of functions in innate and adaptive immunity, autoimmunity, immune metabolic 
diseases, and other areas. Unexpectedly, of all these proposed functions, 
experiments in Kit-independent mast cell deficient mouse strains could only 
recapitulate the unique functions of mast cells in IgE-mediated processes such as 
allergies, anaphylaxis and protection against helminths (Dudeck et al., 2011; 
Feyerabend et al., 2011; Rodewald and Feyerabend, 2012; Sawaguchi et al., 2012). 
 
In humans IgE-dependent processes contribute to diverse pathologies such as 
anaphylaxis, allergic asthma, and hypersensitivity disorders of the skin.  
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Systemic anaphylaxis is the most severe and potentially fatal form of allergy, which 
can occur in response to insect venoms, drugs, and food allergens (Simons, 2010). 
The term allergy describing hypersensitivity reactions was postulated in 1906, Paul 
Portier and Charles Richet already described anaphylaxis in 1902, when they 
observed that dogs immunized against a toxin from the jellyfish Physalia did not 
induce protective immunity but instead died after a second injection of the toxin 
(Portier and Richet, 1902). In the USA, anaphylactic shock is responsible for an 
estimate of 1500 deaths annually (Matasar and Neugut, 2003). Anaphylaxis is 
caused by crosslinking of IgE on the surface of mast cells resulting rapidly in 
degranulation. In particular histamine that is systemically release from mast cells 
causes the symptoms of anaphylaxis such as oedema and reduced blood pressure 
(Simons, 2010). 
Allergic asthma is a disease affecting the airways and is characterized by airway 
hyper-reactivity (AHR), mucus production, eosinophilia and fibrosis in the lungs. 
Clinical parameters such as mast cell infiltration into the airways correlate with 
bronchial hyper responsiveness (Wardlaw et al., 1988), and increased concentrations 
of histamine (Casale et al., 1987) and tryptase (Zhang and Timmerman, 1997) in 
bronchoalveolar lavage (BAL).  
Clinical studies provide strong evidence for a crucial role of IgE and FcɛRI in human 
asthma, as demonstrated by use of the anti-IgE mAb Omalizumab which was shown 
to decrease serum IgE levels and allergen-induced bronchoconstriction (Vichyanond, 
2011).  
The contribution of mast cells to chronic disease is difficult to assess. In order to 
shed light on the specific contribution of mast cells to asthma, animal models may 
provide crucial information on underlying mechanisms. However, animal models of 
asthma are suffering from inherent drawbacks that are mainly due to structural and 
cellular composition of the airways (under physiological conditions murine lungs do 
not contain mast cells), and non-physiological sensitization protocols (mostly very 
rapid sensitization) (Kumar, 2012; Voehringer, 2013). 
Clinically observed hypersensitivity reactions of the skin, such as atopic dermatitis 
(AD), urticaria and IgE-mediated chronic allergic inflammation, have been linked to 
elevated IgE levels and mast cell infiltration into sites of inflammation. As a 
consequence, it is generally assumed that mast cells contribute to the inflammatory 
response. However, to date only few studies have shown to what degree and by 
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which mechanism mast cells contribute to hypersensitivity reactions such as AD. 
Available studies were performed with Kit-dependent mast cell deficiency models 
(Kawakami et al., 2009) and require independent verification.  
1.4. Current treatment of mast cell dependent diseases 
The three pillars of treatment of allergic disease are allergen avoidance, allergen-
specific immunotherapy (SIT), and pharmacological intervention. 
Allergen avoidance in children, to circumvent sensitization, has been explored. 
However, the results of such primary prophylaxis have been disappointing as most 
children became sensitized due to accidental intake minute quantities of antigen, 
which were sufficient for sensitization (Holgate and Polosa, 2008). 
SIT is a therapy that modulates the immune response to allergens. This type of 
therapy is recommended for the treatment of allergic rhinitis, venom hypersensitivity, 
certain drug reactions and mild bronchial asthma. The mechanism of action is based 
on the induction of tolerance by allergen-specific IgG4 antibodies and regulatory T 
cells (TReg). TReg produce large amounts of IL-10 and TGF-β, which attenuates 
allergen-specific TH2 in favor of a TH1 immune response (Wu et al., 2007). 
Pharmacological interventions mainly focus on four classes of substances: 
Corticosteroids, receptor agonists, receptor antagonists and biologics. 
Corticosteroids, suppress inflammation of the asthmatic airways by inhibition of the 
two major pro-inflammatory transcription factors nuclear factor-κB and activator 
protein 1 (Barnes and Adcock, 1998). α/β-adrenoreceptor agonists are 
bronchodilators that bind to their cognate receptors, which triggers a signaling 
cascade that results in smooth muscle relaxation. H1-antihistamines, leukotriene 
modifiers (e.g. CysLTR1 antagonists), and cAMP phosphodiesterase inhibitors (PDE) 
belong to the third category of available pharmacological drugs to treat allergic 
disease. While H1- and CysLTR1 antagonists block the interaction of their respective 
mediator with their cognate receptor on structural cells of the airways, PDE 
suppresses the release of cytokines and other inflammatory signals in immune cells 
(Holgate and Polosa, 2008). 
The fourth class of pharmacological interventions are biologics. Two biologics in use 
are directed against IgE, which is the most prominent indicator and mediator of 
allergic disease. Omalizumab (anti-IgE) was the first mAb to become approved in 
severe asthmatics and binds to soluble IgE (sIgE) at an epitope that overlaps with the 
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FcεRI binding site. As a consequence, binding of Omalizumab to sIgE blocks the IgE-
FcεRI interaction and generates small immune complexes that are cleared from the 
body by a yet undescribed mechanism (Chang et al., 2007b). Apart from clearing 
sIgE, Omalizumab treatment results in the reduction of FcɛRI on the surface of mast 
cells and basophils (Holgate, 2014). IgE‐occupied FcɛRI are structurally stable and 
are maintained on the cell surface, however FcɛRI that are not bound by IgE are 
structurally unstable and are internalized for degradation (Kubo et al., 2001). Mast 
cells and basophils that have reduced levels of IgE‐occupied FcɛRI become 
refractory to antigen-mediated activation (Holgate, 2014). However, sIgE is 
continously produced by memory B cells creating two major drawbacks for the 
treatment with Omalizunmab. Firstly, patients rely on continous treatment for 
maintaining the therapeutic efficacy, secondly lowering the cost-effectiveness 
(Hochhaus et al., 2003). 
In order to target IgE-producing cells, a novel anti-IgE antibody has been developed: 
Quilizumab. It targets the 52 amino acid long M1’ extracellular part of the segment of 
human membrane bound IgE, found on IgE producing B cells (Brightbill and Lin, 
2014). IgE+ B cells are opsonized by the anti-M1’ antibody, and thus can be depleted 
in an Fc-dependent manner. In preclinical models, administration of the anti-M1’ 
antibody reduced de novo IgE production by more than 90%, which was found to be 
the result of depletion of IgE-positive memory B cells and plasmablasts (Brightbill et 
al., 2010). However, in humans Quilizumab was only able to reduce total IgE by 20-
30% which suggests that 70-80% of IgE is produced by M1’ negative cells, most 
likely plasma cells in the bone marrow (Gauvreau et al., 2014). 
 
Mild forms of allergic diseases (allergic rhinitis) can be treated with anti-histamines, 
leukotriene antagonists or immunological desensitization. However, more severe 
forms of disease, such as asthma and atopic dermatitis, require a reduction of 
systemic inflammation by administration of broad acting immunosuppressive agents 
such as oral or intravenous corticosteroids to effectively alleviate symptoms (Leung 
and Bieber, 2003). However, systemic immunosuppressive therapies result in 
pleiotropic side effects such as susceptibility to infection (Nesbitt, 1995; Seale and 
Compton, 1986). 
Particularly for severe asthmatics, defined by persisting symptoms despite treatment 
with high-dose inhaled steroids, novel therapeutic agents are urgently required (D 
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Amato et al., 2014). In addition, a subgroup of these patients may not be able to 
sufficiently control the disease, and thus have a particular high risk of morbidity and 
mortality, requiring frequent health-care services, such as emergency visits, 
hospitalizations and additional consumption of drugs for recurrent exacerbations 
(Pakhale et al., 2011; Serra-Batlles et al., 1998). Patients with severe/refractory 
asthma are a greater burden on industrialized nations healthcare systems than 90% 
of asthma patients with well controlled asthma (Holgate and Polosa, 2008). While 
steroids are the mainstay of treatment for severe asthma patients, Omalizumab has 
been reported to provide benefit for such patients by improving asthma symptoms, 
increasing disease control, reducing exacerbations and improving quality of life (D 
Amato et al., 2014). 
Many of the current treatment strategies for allergic disease rely either on the 
neutralization of mast cell derived molecules (histamine and leukotriene), aim at 
reducing the activation of mast cells (corticosteroids, cromolyn sodium, and anti-IgE) 
or interfere with survival and proliferation of mast cells (Kit inhibitor) (Reber and 
Frossard, 2014). However, there is yet no therapeutic approach directed specifically 
against mast cells that would alleviate all mast cell-dependent symptoms and thereby 
reduce burden on the patients and on the healthcare providers. 
Pharmaceutical companies are heavily investigating cell-directed therapies, using 
cell-depleting antibodies, due to their specific actions, reduction in side effects, and 
good safety profile. The key to cellular targeting (i.e. cellular depletion) of mast cells 
would be to find specific surface molecules that ensure safety and specificity. 
Experimentally, the therapeutic intervention directed specifically against mast cells 
has only scarcely been explored. Experimental studies on mice that used mAb 
directed against FcεRI or CD117 (Kit) have shown that mast cells, which express 
both FcεRI and Kit, can be targeted with cell-depleting antibodies (Brandt et al., 
2003). Unfortunately, Kit is expressed in many cells beyond mast cells, thus the 
treatment of mice resulted in simultaneous depletion of cajal cells and hematopoietic 
progenitor cells (Daëron and Jönsson, 2012). Moreover, antibodies targeting the 
FcεRI pose high risk of activating mast cells, which could result in anaphylactic 
shock. 
Apart from experimental work in mice, Siglec-8 has recently been identified as a 
human mast cell restricted receptor that may be suitable for the development of an 
antibody-dependent cytotoxic targeting approach (Kiwamoto et al., 2012). 
Introduction 
 19 
1.5. Antibody-based mechanisms of cell ablation 
Apart from discovering the mast cell, Paul Ehrlich also conceptualized the “magic 
bullet” hypothesis of specific recognition and elimination of malignant cells by 
antibodies. Since the discovery of hybridoma technology by Georges Köhler in 1975 
the development of antibodies for therapeutic use has surged. Antibodies may target 
tumour cells by binding to cell surface antigens that are differentially expressed in 
cancer. One of the first antigens that were found to be suitable candidates in the 
clinics was CD20. The antibody rituximab targets CD20 in non-Hodgkin B cell 
lymphoma and was one of the most prominent antibody-based cytotoxic drugs to be 
approved for therapeutic use. Investigation of the killing mechanism revealed that 
three different pathways induce cell death. First, direct signalling of bound CD20 
interferes with essential cellular functions. Secondly, antibody opsonisation initiates 
the complement cascade resulting in lysis by the membrane attack complex. And 
lastly, cell death may be induced by antibody-dependent cellular cytotoxicity (Weiner 
et al., 2010). 
 
An overview of the anti-cancer mechanisms of mAbs with direct cytotoxic effect on 
target cells is depicted in Figure 3. 
Fc-mediated effector engagement includes the cell-mediated killing of antibody 
opsonized tumour cells by Fcγ-expressing innate immune cells as well as 
complement dependent lysis by membrane attack complex. In antibody-dependent 
cellular phagocytosis, mononuclear phagocytes that express FcγR bind to the Fc-
portion of the antibodies thereby inducing phagocytosis of the target cell. In antibody-
dependent cell-mediated cytotoxicity (ADCC), NK cells bind to cell bound antibodies 
via their FcγR, and induce the release of cytotoxic granules containing perforin and 
granzymes that kill the target cell (Scott et al., 2012). During complement dependent 
lysis C1q molecules bind to Fc-portions of opsonising antibodies, thereby initiating 
the alternative complement cascade resulting in generation of the membrane attack 
complex (Weiner et al., 2012). 
Direct cytotoxicity of mAbs may be induced by attachment of a cytotoxic comjugates 
(mostly toxins but also some radioactive or photoactivateable compounds) to the 
antibody. For cytotoxicity of such an antibody-drug conjugate (ADC), target:toxin 
complex internalisation is required. In contrast, ADCC requires cell surface exposition 
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for efficient killing (Trail, 2013). In addition, ligand binding itself has, in several 
instances, been identified to induce cell death (Rituximab).  
Non-restricted activation of T cells comprises bispecific antibodies and antibody-
derived recombinant proteins that possess more than one targeting domain. The 
mechanism of action is based on the simultaneous engagement of target cell and T 
cell to facilitate anti-tumour activity (Spiess et al., 2015). 
The third major cell-directed antibody-mediated anti-tumour mechanism is based on 
blocking of inhibitory signals on naturally occurring cytotoxic lymphocytes within the 
tissues. A balance of activating and inhibitory signals tightly regulates the activation 
of NK cells. By engagement of the activating receptors on NK cells or blocking of 
inhibitory receptors on cytotoxic T cells the balance can be shifted towards cellular 
activation and tumour cell killing (Weiner et al., 2012). 
 
 
Figure 3: Non-humoral antibody-mediated cell targeting (tumour cell example) 
Cell depletion mechanisms by monoclonal antibodies are versatile. Here, four groups 
of anti-cell mechanisms are depicted. Fc-mediated immune effector engagement, 
direct cytotoxic mechanisms, non-restricted activation of cytotoxic t cells, and 
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blockade of lymphocyte inhibitory signals. Figure was adapted from (Weiner et al., 
2012). 
 
During the last few decades’ researchers have optimized the efficacy of mAbs for 
clinical utility. For example, structural engineering of the antibody sequence or 
glycosylation patterns has improved immunogenicity and immune effector cell 
engagement. In this regard it has been shown that removal of the core fucose within 
the antibody heavy chain glycosylation, increases the affinity for activating FcγRs 
expressed on myeloid cells and thereby increases the cell depleting activity 
(Nimmerjahn and Ravetch, 2011). 
 
Mast cells, which are involved in numerous allergic pathologies, cannot be targeted 
by conventional therapeutics. Specific removal of mast cells by means of antibody 
targeting would interrupt the allergic cascade and is expected to offer significant 
benefit for patients. In order to develop such a mAb-mediated mast cell targeting 
approach I aim to establish proof of principle in a well-controlled system provided by 
our newly developed transgenic mouse model expressing an ectopic cell surface 
receptor selectively on MC. To transfer our findings towards the clinics I aim to 
identify novel mast cell specific cell surface markers by mass spectrometry and 
elucidate their mast cell targeting potential in mice. 
 
1.6. Aims of the study 
In principle any cell in the body may be the target of a cell-depleting antibody. Once a 
cell-type specific cell surface protein is recognized by a monoclonal antibody, 
immune cells can bind and eliminate the target cell. This strategy has been 
successfully adapted for several malignancies, such as B cell lymphoma, for which 
an Ab drug, Rituximab (anti-CD20), was developed. Due to their high degree of 
specificity mAb-based therapies are, in general, well tolerated. However, the efficacy 
mainly depends on the specificity of the target and the turnover of the target cell 
(Scott et al., 2012). Mast cells in particular, have been reported to exhibit 
extraordinary longevity in tissues, which would be highly advantageous for the 
efficacy of a mast cell ablation strategy (Dudeck et al., 2011; Julia Scholten, 2009).  
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With this study I aim to develop and test strategies to efficiently and safely ablate 
mast cells by monoclonal antibody-mediated mechanisms. The objectives are: 
1.) Identification and verification of a suitable target molecule on the surface of 
mouse and human mast cells 
2.) Exploration of different antibody-dependent mast cell ablation mechanisms for 
their efficacy 
3.) Investigation on safety of mAb-dependent mast cell ablation in mice 
4.) Functional test of mast cell ablation in a relevant animal model of human disease  
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals 
All chemicals not listed below were either purchased from Merck and Fluka or Sigma-
Aldrich. 
 
 
 
2.1.2. Kits 
Kit Company 
Pierce™ Antibody Clean-up Kit 
Alexa Fluor® 647 Antibody Labeling Kit 
pHrodo™ Red, succinimidyl ester 
EZ-Link™ NHS-PEG4-Biotin, No-Weigh™ Format 
Pierce™ Fluorescence Biotin Quantitation Kit 
CellTiter-Blue® Cell Viability Assay 
ThermoFisher Scientific 
ThermoFisher Scientific 
ThermoFisher Scientific 
ThermoFisher Scientific 
ThermoFisher Scientific 
Promega 
 
2.1.3. Enzymes 
Enzymes Company 
Collagenase Type VIII 
Collagenase Type IV 
Hyluronidase 
DNase I 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
 
2.1.4. Anti-mouse Antibodies 
Fluorophore Dilution Supplier Clone Isotype 
CD3e BV421 1:200 BioLegend 17A2 Rat IgG2b, κ 
CD3e APC eF780 1:25 eBioscience 17A2 Rat IgG2b, κ 
CD11b BV421 1:800 BioLegend M1/70 Rat IgG2b, κ 
CD11b PeCy7 1:400 eBioscience M1/70 Rat IgG2b, κ 
CD11b PerCP-Cy5.5 1:400 eBioscience M1/70 Rat IgG2b, κ 
CD11c BV421 1:100 BioLegend N418 Armenian hamster IgG 
CD13 BV421 1:100 BD WM15 Mouse IgG1, κ 
CD19 BV421 1:400 Biolegend 6D5 Rat IgG2a, κ 
CD19 BV605 1:800 Biolegend 6D5 Rat IgG2a, κ 
CD31 PE 1:100 BD MEC13.3 Rat IgG2a, κ 
CD34 FITC 1:25 eBioscience RAM34 Rat IgG2a, κ 
CD43 APC 1:100 BD S7 Rat IgG2a, κ 
CD45 APC eF780 1:400 eBioscience 30-F11 Rat IgG2b, κ 
CD45 BV785 1:400 Biolegend 30-F11 Rat IgG2b, κ 
Reagent Company 
DNP11-OVA  
EDTA disodium salt  
SYTOX Blue Dead Cell Stain 
SYTOX Green Dead Cell Stain 
RBC lysis buffer (10x) 
BioCat 
Gibco 
Invitrogen 
Invitrogen 
eBioscience 
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CD45 Pe Cy7 1:400 eBioscience 30-F11 Rat IgG2b, κ 
CD47 PE 1:100 Biolegend miap301 Rat IgG2a, κ 
CD49b APC 1:100 eBioscience DX5 Rat IgM 
CD49d FITC 1:100 BD 9C10(MFR4.B) Rat IgG2a, κ 
CD56 A647 1:100 R&D #809220 Rat IgG2a, κ 
CD63 PE 1:100 Biolegend NVG-2 Rat IgG2a, κ 
CD81 PE 1:100 eBioscience Eat-2 Armenian hamster IgG 
CD98 FITC 1:100 eBioscience RL388 Rat IgG2a, κ 
CD107a PE 1:100 Biolegend 1D4B Rat IgG2a, κ 
CD117 APC 1:800 BD 2B8 Rat IgG2b, κ 
CD117 APC eF780 1:800 eBioscience 2B8 Rat IgG2b, κ 
CD117 PE 1:800 eBioscience 2B8 Rat IgG2b, κ 
CD147 PE 1:100 Biolegend OX-144 Rat IgG1, κ 
CD171 APC 1:100 R&D FAB5674A Rat IgG2a, κ 
CD200r3 PE 1:100 Biolegend Ba160 Rat IgG2a, κ 
CD317 PE 1:200 eBioscience ebio927 Rat IgG2b, κ 
F4/80 BV605 1:100 Biolegend BM8 Rat IgG2a, κ 
F4/80 PE-Cy7 1:100 eBioscience BM8 Rat IgG2a, κ 
FcεRI PE 1:100 eBioscience MAR-1 Armenian hamster IgG 
Gr-1 BV421 1:800 Biolegend RB6-8C5 Rat IgG2b, κ 
IgE BV 786 1:200 BD R35-72 Rat IgG1, κ 
IgE FITC 1:200 BD R35-72 Rat IgG1, κ 
T1/ST2 eFluor710 1:400 eBioscience RMST2-2 Rat IgG2a, κ 
Integrin ß7 PE 1:100 BD M293 Rat IgG2a, κ 
P2X7R A488 1:100 Biolegend 1F11 Rat IgG2b, κ 
Isotype PE 
 
eBioscience eBR2a Rat IgG2a, κ 
Isotype PE 
 
BD A95-1 Rat IgG2b, κ 
Isotype PE 
 
eBioscience eBio299Arm Armenian hamster IgG 
Isotype PE 
 
Invitrogen R104 Rat IgG1, κ 
Isotype eFluor710 
 
eBioscience eBR2a Rat IgG2a, κ 
Isotype FITC 
 
Biolegend RTK2758 Rat IgG2a, κ 
Isotype FITC 
 
eBioscience eB149/10HS Rat IgG2b, κ 
Isotype FITC 
 
eBioscience eBRG1 Rat IgG1, κ 
Isotype APC 
 
eBioscience eBRM Rat IgM 
Isotype APC 
 
Biolegend RTK2758 Rat IgG2a, κ 
Isotype A647 
 
Biolegend RTK2758 Rat IgG2a, κ 
Isotype BV421 
 
Biolegend RTK2071 Rat IgG1, κ 
MsIgG2a eFluor710 eBioscience m2a-15F8 Rat IgG1, κ 
 
2.1.5. Anti-human Antibodies 
Fluorophore Dilution Supplier Clone Isotype 
CD3 BV421 1:100 Biolegend OKT3 Mouse IgG2a,k 
CD4 PE 1:100 Dako MT 310 Mouse IgG1,k 
CD4 Pe-Cy7 1:100 eBioscience SK3 Mouse IgG1,k 
CD14 BV605 1:100 Biolegend M5E2 Mouse IgG2a,k 
CD16 FITC 1:100 eBioscience eBioCB16 Mouse IgG1,k 
CD19 Alexa Fluor 700 1:100 Biolegend HIB19 Mouse IgG1,k 
CD26 PE 1:100 Biolegend Ba5b Mouse IgG2b,k 
CD36 PE 1:100 Biolegend 5-271 Mouse IgG2a,k 
CD44 PE 1:100 Biolegend BJ18 Mouse IgG1,k 
CD45 BV785 1:100 Biolegend HI30 Mouse IgG1,k 
CD51 PE 1:100 Biolegend NKI-M9 Mouse IgG2a,k 
CD54 PE 1:100 Biolegend HA58 Mouse IgG1,k 
CD59 PE 1:100 Biolegend p282 (H19) Mouse IgG2a,k 
CD63 PE 1:100 Biolegend H5C6 Mouse IgG1,k 
CD82 PE 1:100 Biolegend ASL-24 Mouse IgG1,k 
CD92 APC 1:100 BD VIM15 Mouse IgG1,k 
CD107a PE 1:100 Biolegend H4A3 Mouse IgG1,k 
CD117 APC 1:100 eBioscience YB5.B8 Mouse IgG1,k 
CD117 PE 1:100 eBioscience YB5.B8 Mouse IgG1,k 
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CD123 PerCP Cy5.5 1:100 eBioscience 6H6 Mouse IgG1,k 
CD171 PE 1:100 eBioscience eBio5G3 Mouse IgG2a,k 
CD193 APC-Cy7 1:100 Biolegend 5E8 Mouse IgG2b,k 
CD203c PE 1:100 eBioscience NP4D6 Mouse IgG1,k 
CD312 PE 1:100 Miltenyi REA302 Human IgG1 
FcεRIα APC 1:100 eBioscience AER-37 Mouse IgG2b,k 
FcεRIα PE 1:100 eBioscience AER-37 Mouse IgG2b,k 
IgE FITC 1:100 eBioscience IgE21 Mouse IgG1,k 
MRGPRX2 1:100 Biolegend K125H4 Mouse IgG2b,k 
Isotype APC  eBioscience P3.6.2.8.1 Mouse IgG1,k 
Isotype PE  Biolegend MOPC-173 Mouse IgG2a,k 
Isotype PE  BD 55617 Mouse IgG1,k 
Isotype PE  eBioscience eBMG2b Mouse IgG2b,k 
 
2.1.6. Media and supplements for cell culture 
 
Media, buffers and supplement Supplier 
DMEM with GlutaMAX I   
FCS (fetal calf serum) 
HBSS (w/o CaCl2, w/o MgCl2, w/o phenol red) 
IMDM with GlutaMAX I  
MEM non-essential amino acids (100x)  
MEM sodium pyruvate (100mM = 100x)  
β-mercaptoethanol  
PBS (Dulbecco’s w/o CaCl2, w/o MgCl2)  
Penicillin-Streptomycin 
(100x, 10.000U penicillin/ml, 10.000 µg 
streptomycin/ml)  
Mouse Interleukin-3 
Mouse Stem cell factor (SCF) 
 
Recombinant human Interleukin 4 (rhIL-4) 
Recombinant human Stem cell factor (rhSCF) 
Gibco 
HyClone 
Gibco 
Gibco 
Gibco 
Gibco 
Gibco 
Gibco 
 
Peprotech 
Peprotech 
Supernatant from an Il-
3/SCF gene transfected cell 
line (Karasuyama and 
Melchers, 1988) 
 
 
 
Medium for peritoneal- (PMC) and bonemarrow-derived mast cells (BMMC):  
 
IMDM 
10 % FCS 
100 µM MEM Non-essential amino acids 
1 mM MEM Sodium pyruvate 
100 U/ml Penicillin  
100 U/ml Streptomycin 
50 µM β-mercaptoethanol  
1 % SCF conditioned medium 
1 % IL-3 conditioned medium  
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Medium for human mast cell culture: 
 
IMDM 
10% FCS 
20 ng/ml rhIL-4 
100 mg/ml rhSCF 
100 U/ml Penicillin  
100 U/ml Streptomycin 
2.1.7. Buffers and solutions 
1x PBS    9.55 g/l of a D-PBS ready-to-use mixture (Gibco) 
8 g/l NaCl, 
0.2 g/l KCl 
1.15 g/l Na2HPO4 
0.2 g/l KH2PO4 
 
Mota’s fixative  4 g lead acetate (basic) 
    30 ml 100% ethanol 
    2-3 drops of glacial acetic acid 
 
Acidic toluidine blue 0.5 g of toluidine blue 
    50 ml 100% ethanol 
    2-3 drops of glacial acetic acid 
2.1.8. Cells and animals 
2.1.8.1. Cell lines 
CHO-SCF  CHO cells transfected with mouse SCF cDNA to produce SCF, 
Genetics Institute, Boston 
 
X63-IL3  X63 myeloma cell line transfected with a mouse IL-3 cDNA construct to 
secrete large quantities of the cytokine IL-3 (Karasuyama and 
Melchers, 1988).  
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H5C6  P3X653-Ag8 hybridoma cells expressing anti-hCD63 mouse IgG1,κ 
(clone H5C6). H5C6 was deposited to the DSHB by August, J.T. / 
Hildreth, J.E.K. (DSHB Hybridoma Product H5C6) 
2.1.8.2. Primary human mast cells 
Human mast cells were isolated from skin and fat tissue obtained from 
Proaesthetics.gmbh after written and oral consent of patients undergoing cosmetic 
surgery (Ethics approval no. S-377/2015). Human lung mast cells were isolated from 
bronchial biopsies obtained during lung surgery at the Thorax Clinics Heidelberg after 
written and oral consent (Ethics approval no. S-381/2014). Human colon mast cells 
were isolated from bowel biopsies obtained during bowel surgery at the University 
Hospital Heidelberg after written and oral consent approval. 
2.1.8.3. Mouse strains 
Inbred strains 
 
The inbred mouse strains C57BL/6 and BALB/c were originally obtained from 
Charles River or Harlan and maintained in the mouse facilities of the DKFZ in 
Heidelberg under specific pathogen-free (SPF) conditions. 
 
Cpa3Cre/+ mice 
 
Cpa3Cre/+ mice were generated from targeted E14.1 ES-cells. ES cell clones bearing 
the Cpa3Cre/+ knock-in allele were injected into C57BL/6 blastocysts to produce 
chimeric mice (Feyerabend et al., 2011). Subsequent crossing to C57BL/6 
transmitted the targeted allele through the germ line. Heterozygous offspring were 
then used to backcross the Cpa3Cre/+ allele onto C57BL/6 and BALB/c background. 
All strains were kept under specific pathogen-free (SPF) conditions at the animal 
facilities of the DKFZ in Heidelberg. 
 
Cpa3hCD4/+ mice 
 
Cpa3hCD4/+ mice were generated from targeted E14.1 ES-cell clones following 
blastocyst injection (Feyerabend, 2007). Homozygous Cpa3hCD4/hCD4 mice were 
derived from intercrosses of Cpa3hCD4/+ mice on the C57BL/6 background. All strains 
were kept under SPF conditions at the animal facilities of the DKFZ in Heidelberg. 
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2.1.9. Equipment 
Laboratory equipment Company 
Cytospin4 (centrifuge)  
Digital thermometer Qtemp 200 
Heraeus Fresco 17 (benchtop centrifuge)  
Heraeus Megafuge 40R 
Inverse light microscope Primo Vert 
Light microscope DM LB2 
Light microscope Lab.A1 
Light Microscope Axioplan 
LSRFortessa (FACS analyzer) 
Aria (Cell sorter) 
Fusion (Cell sorter) 
Cellometer Auto 2000 
Shandon 
VWR International 
Thermo Scientific 
Thermo Scientific 
Zeiss 
Leica  
Zeiss 
Zeiss 
BD Bioscience 
BD Bioscience 
BD Bioscience 
Nexcelem 
 
2.1.10. Software 
Flow cytometry data were acquired and analysed with FacsDiva software (BD 
Bioscience) or FlowJo software (Treestar). Microscopic images were acquired using 
ZEN 2011 lite software and further processed with Photoshop CS (Adobe). 
Statistical analyses and graphs were generated with Prism 6 (Graphpad).  
 
2.2. Methods 
2.2.1. Cell Biology 
2.2.1.1. Preparation of cells from murine organs 
2.2.1.1.1. Recovery of peritoneal exudate cells (PEC) 
Mice were euthanized by CO2 asphyxiation. The peritoneum was opened by a small 
cut. The peritoneal cavity was flushed successively with a total of 10 ml 37°C pre-
warmed FACS buffer and the recovered PEC were collected on ice. 
2.2.1.1.2. Digestion of skin, tongue, trachea and fat for analysis of mast cells 
Ear/back skin, tongue, trachea and fat were minced and re-suspended in 500 µl 
DMEM containing 0.025 mg/ml DNase I (Sigma-Aldrich) and 1mg/ml collagenase 4 
(Sigma-Aldrich). The minced tissues were incubated at 37°C under shaking at 700 
rpm for 20 min. The supernatant, containing liberated cells, was collected on ice and 
2 mM EDTA and 5% FCS were added to inhibit remaining enzymatic activity. 
Undigested tissue clumps were subjected to further digestion rounds with fresh 
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digestion mix until the tissues were completely digested. Finally, the cells were 
pelleted, re-suspended in FACS buffer and analysed.,  
2.2.1.1.3. Isolation of intra-epithelial leukocytes from the stomach 
Stomach was removed from the mouse and cut open longitudinally. Washing with 
FACS buffer cleared undigested food away. Subsequently the stomach was minced 
and re-suspended in 1 ml Ca2+/Mg2+ free HBSS containing 4 mM EDTA. The minced 
stomach was then incubated at 37 °C under shaking at 700 rpm for 20 min. Tissue 
fragments were separated from intra-epithelial leukocytes by filtration through a 100 
µm cell strainer. Finally, the cells were pelleted, re-suspended in FACS buffer and 
utilized for FACS.  
2.2.1.2. Preparation of cells from human organs 
2.2.1.2.1. Digestion of skin, lung and fat for analysis of mast cells 
Skin was obtained from either cosmetic abdominoplasty, labioplasty, blepharoplasty 
or breast reduction surgery. Specimens were minced with scissors or scalpels and 
resuspended in 10 ml of PBS with 0.2 mg/ml Collagenase 8 (Sigma), 0.025 mg/ml 
DNase I (Sigma-Aldrich) and 0.1 mg/ml Hyluronidase (Sigma) per gram tissue. The 
minced tissues were incubated at 37°C under shaking at 150 rpm for 120 min. 
Undigested tissue fragments were filtered through gauze and centrifuged at 1200rpm 
for 5 min. Pellets were washed with PBS +5% FCS + 2 mM EDTA and filtered 
through 100 µm cell strainer. Filtered cells were used for antibody staining or 
magnetic enrichment. 
Lung tissue was obtained from patients undergoing lobectomy surgery due lung 
cancer (mostly non-small-cell-lung-carcinoma). Colon tissue was obtained from 
patients undergoing partial bowel resection due to bowel cancer. In either case, 
patients did not receive chemotherapeutic treatment before surgery. Specimens were 
minced with scissors or scalpels and resuspended in 10 ml of PBS with 0.2 mg/ml 
Collagenase 8 (Sigma) and 0.025 mg/ml DNase I (Sigma-Aldrich) per gram tissue. 
The minced tissues were incubated at 37°C under shaking at 150 rpm for 40 min. 
The supernatant, containing liberated cells, was collected on ice and 2 mM EDTA 
and 5% FCS were added to inhibit remaining enzymatic activity. Undigested tissue 
clumps were subjected to further digestion rounds with fresh digestion mix until the 
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tissues were completely digested. Finally, the cells were pelleted, re-suspended in 
FACS buffer and analysed by flow cytometry. 
2.2.2. Flow Cytometry 
2.2.2.1. Antibody staining 
Cells were stained in 96-well V-bottom plates or in 1.5-ml tubes. Up to 5 x 106 cells 
were incubated in 50 µl FACS buffer. Prior to antibody staining, cells were incubated 
for 20 min with 0.28 mg/ml mouse IgG (Jackson ImmunoResearch Laboratories) to 
block Fcγ-receptors. The cells were then centrifuged and resuspended in FACS 
buffer containing the diluted fluorochrome-coupled antibodies. Cells were incubated 
for 30 min on ice protected from light. After staining, cells were washed once with 1ml 
FACS buffer in 1.5-ml tubes, or with 200 µl FACS buffer in 96-well plates. If 
necessary, cells were incubated for another 20 min with a secondary antibody and 
washed accordingly. The optimal working concentration for each antibody was 
determined by separate titration experiments and is listed under table 1. 
Finally, cells were re-suspended in FACS buffer and analysed on a LSRFortessa (BD 
Bioscience). Data are displayed as dot plots or histograms using FlowJo software 
(Treestar).  
Flow cytometry data was normalized across experiments by calculating the staining 
index ( !"# !"#$%#!!"# !"!"#$% !"#$%"&! ! !" !"# !"#$%&' !"#$%"& ) (Maecker et al., 2004). 
2.2.2.2. Exclusion of dead cells 
To exclude dead cells from FACS analysis, 1 µM SYTOX Blue or Green Dead Cell 
Stain (Invitrogen) was added to the cell samples 5 min before analysis.  
2.2.2.3. Magnetic enrichment of Kit+ cells  
Peritoneal cavity cells were incubated with CD117 specific magnetic micro beads for 
20 min at 4°C. Cells were then spun down and washed with FACS buffer. A single 
MACS LS column was placed into the magnet and equilibrated with cold FACS 
buffer. Magnetically labelled cells were applied to the column and unlabelled cells are 
not retained in the magnetic field. After washing, CD117+ cells could be eluted from 
the column by removing it from the magnet and flushing the cells with cold FACS 
buffer from the column. Cells were then pelleted and counted and prepared for 
subsequent analysis or further purification on the cell sorter. 
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2.2.2.4. Measurement on BD Fortessa 
Antibody stained cells were measured on a BD LSR Fortessa equipped with a violet 
(405 nm), green (488 nm), yellow (560 nm), and red laser (633 nm). Cells were first 
gated based on their forward / sideward scatter characteristics, followed by gating on 
single cells and live cells (Sytox negative). Cells were further characterised 
depending on the antibodies used within the individual experiments. 
2.2.2.5. Murine cell sorting on BD Aria 
Antibody stained peritoneal cavity cells or CD117+ selected peritoneal cells were 
sorted on a BD Aria cell sorter using a 100 µm nozzle at 20 PSI. Cells were sorted 
into pure PBS. For proteomics experiments, the sorted cells were immediately 
centrifuged at 2000 rpm for 5 minutes and shock frozen in liquid nitrogen. Cells were 
stored at -80°C. 
2.2.2.6. Human cell sorting on BD Fusion 
Antibody stained CD117+ selected cells from skin or fat tissue were sorted on a BD 
FUSION cell sorter using a 100 µm nozzle at 20 PSI. Cells were sorted into pure 
PBS. 
2.2.2.7. Cytospins & Toluidine blue staining 
Sorted human mast cells were resuspended at 10.000 cells per 200 µl in PBS. The 
cell suspension was added to the cytospin slides. The cytospin slides were inserted 
into a Cytospin™ 4 Cytocentrifuge and centrifuged at 700 rpm for 5 min. with 
acceleration set to medium.  
Cytospun human mast cells were fixed by adding several drops Mota’s fixative 
directly onto the cells. Cells were incubated for 10 min and fixative was replenished 
twice to prevent drying of the cells. The slides were then rinsed with water to remove 
the fixative. Two to three drops of acidic toluidine blue were added directly onto the 
cells and slides were incubated for 20 min at room temperature. Afterwards they 
were rinsed with water and blotted dry. The cells were then embedded in Permount 
and enclosed by a coverslip. Images were taken on a Zeiss Axioplan upright 
microscope with a 40x objective using the ZEN 2011 lite software suite. 
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2.2.3. Procedures of animal experimentation 
2.2.3.1. Antibody injections 
Mice were injected intraperitoneally (i.p.) or intravenously (i.v.) with 30-90 mg/kg (0.3 
– 2.7 mg) of TNX355 or afucosylated TNX355 antibody with varying numbers of 
injections and treatment intervals. In case of immunotoxin treatment, mice were 
injected i.v. with either 100 µg of 1:1 molar mixture of biotinylated CD63 antibody and 
streptatividin-saporin (SAP) (60 µg mAb + 40 µg SAP) or with 40 µg SAP alone. All 
injections were performed in 200 µl PBS. 
2.2.3.2. Passive systemic anaphylaxis assay 
Mice were first sensitized with IgE directed against dinitrophenol (DNP). DNP-specific 
IgE binds the high affinity IgE receptor (FcεRI) on the cell surface of mast cells and 
basophils. Upon challenge with antigen, mast cells and basophils become activated, 
which in mice results in hypothermia. Mice were sensitized by i.v. injection of 20 µg 
mouse anti-DNP-IgE (clone SPE-7, Sigma). 24 h later, the mice were challenged by 
i.v. injection of 20 µg DNP11-OVA (Biocat). The anaphylactic response was monitored 
by change in core (rectal) body temperature every 10 min over a period of 3 h using 
the digital thermometer Qtemp 200 (VWR International, Germany) 
2.2.4. Cell culture 
2.2.4.1. General cell culture methods 
Murine cells were kept at 37 °C, 95% humidity and 5% CO2. Human cells were kept 
at 37 °C, 95% humidity and 10% CO2. Unless otherwise indicated, standard handling 
of the cells during experiments was as follows: Cells were kept on ice, standard 
washing buffer was PBS containing 5% FBS and 2 mM EDTA (FACS buffer). 
Standard centrifugation was 5 min at 138 g (1200 rpm) in the Heraeus Fresco 17 
centrifuge, or 5 min at 314 g (1200 rpm) in the Heraeus Megafuge 40R at 4 °C. 
2.2.4.2. Determination of the cell number 
An aliquot of cells was diluted in an appropriate volume of FACS buffer and 20 µl of 
the cell suspension mixed with the same volume of AOPI solution.  
20 µl of this dilution were applied to a counting slide, which was subsequently 
inserted into a Nexcelem Cellometer Auto 2000 cell counter. Acridine Orange and 
Materials and Methods 
 33 
Propidium Iodide-negative cells (nucleated living cells) were used to calculate the cell 
number. 
2.2.4.3. Generation of bone marrow-derived mast cells (BMMC) 
Femurs of mice were crushed with a mortar and pistil, and cells were filtered through 
a 100 µm cell strainer. Whole bone marrow cells were pelleted, re-suspended in  
1 ml BMMC medium and counted.  Cells were adjusted to 1 x 106 cells/ml in BMMC 
medium and plated into 6-well plates (3 ml/well). One ml medium was replaced by 
fresh BMMC medium on a biweekly basis. After two weeks non-adherent cells were 
transferred into new 6-well plates. After four to five weeks of culture the purity of the 
differentiated mast cells (FcεRI+ and Kit+) was at least 95 % as analysed by flow 
cytometry. The optimal cell density is 0.5 - 1 x 106 cells/ml and BMMC were split 
accordingly.  
2.2.4.4. Generation of peritoneal cell-derived mast cells (PMC) 
Peritoneal cells were collected by lavage as described earlier. Cells were pelleted, 
re-suspended in 1 ml BMMC medium and counted. Cells were adjusted to 1 x 106 
cells/ml in BMMC medium and plated into 6-well plates (3 ml/well). 1 ml medium was 
replaced by fresh BMMC medium on a weekly basis. After one week non-adherent 
cells were transferred into new 6-well plates. After two to three weeks of culture the 
purity of mast cells (FcεRI+ and Kit+) in the culture was at least 95% as analysed by 
flow cytometry.  
 
2.2.4.5. Antibody internalisation assay 
pHrodoRed coupled H5C6 or isotype control antibody (msIgG1) was incubated with 
primary human fat and skin mast cells at 10 µg/ml at 37 °C. After different time points 
cells were resuspended in 10x volume of FACS buffer and centrifuged at 1200 rpm 
for 5 minutes. Cells were then resuspended in FACS buffer and analysed by flow 
cytometry. The pHrodoTM red dye has excitation and emission maxima of 
approximately 560 nm and 585 nm. At neutral pH pHrodoRed does not emit 
fluorescence. Internalisation of the dye bound to the antibody, and entry into acidic 
(ph>7) compartments induces a conformational change in the dye resulting in 
fluorescence emission after excitation at 560 nm. Fluorescence at that wavelength  
as detected by flow cytometry, measured in the PE-channel. 
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2.2.4.6. In-vitro mast cell killing assay 
10.000 peritoneal- and bone marrow-derived mast cells were incubated with different 
amounts of 1:1 molar mixed anti-CD63-biotin (clone NVG-2) and streptavidin-saporin 
in a 96 well plate in 100 µl growth medium. After 72 hours at 37 °C the amount of 
viable cells was assessed by the CelllTiter-Blue viability assay. Briefly, 10 µl of 
reagent were added to 100 µl of cell suspension. The cells were then incubated for 2 
hours at 37 °C. The metabolic conversion of the redox dye (resazurin) into a 
fluorescent end product (resorufin) was detected at 560Ex/590Em in a fluorescent 
plate reader. Cells treated with 10 µM Mefloquine, which has been reported to induce 
mast cell apoptosis in vitro, served as a positive control (Paivandy et al., 2014).  
 
2.2.5. Molecular Biology 
2.2.5.1. Sample preparation for mass spectrometry 
Peritoneal cavity exudate cells of 6-8 week old C57BL/6J Cpa3+/+, C57BL/6J 
Cpa3Cre/+ and FACS sorted peritoneal mast cells of C57BL/6J Cpa3+/+ mice were 
pelleted and frozen in liquid nitrogen. Cells were lysed in 0.1% RapiGest (Waters) 
and 50 mM (NH4)HCO3, extracted proteins were reduced and alkylated with 5 mM 
DTT and 10 mM iodoacetamide. Impurities were removed by precipitation with TCA 
and washing with acetone. Proteins were then digested overnight with sequencing-
grade modified trypsin (Promega). Peptides were labelled differentially with stable 
isotope dimethyl labels on a column as described previously (Boersema et al., 2009). 
Labelled peptides were mixed 1:1:1 (i.e. from the three samples) according to cell 
number (50.000 cells) and separated by offline high pH reverse phase fractionation 
over a 90-minute gradient on a C18 column (Phenomenex) with an Agilent 1200 
Infinity high-performance liquid chromatography (HPLC) system. Thirty-two fractions 
were collected and subsequently pooled into 10 fractions. Pooled fractions were 
dried under vacuum centrifugation, reconstituted in 4% acetonitrile/ 1% formic acid 
and then stored at -80 °C until LC-MS analysis. 
2.2.5.2. Liquid chromatography–electrospray ionization–tandem mass 
spectrometry 
Pooled peptide fractions were separated with the nanoACQUITY UPLC system 
(Waters) fitted with a trapping column (nanoAcquity Symmetry C18). Peptides were 
separated on a 120-minute gradient and were analyzed by electrospray ionization-
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tandem mass spectrometry (ESI-MS/MS) on a linear trap quadrupole Orbitrap Velos 
Pro (Thermo Fisher Scientific). Full-scan spectra from a mass/charge ratio of 300 to 
1,700 at a resolution of 30.000 full width at half maximum were acquired in the 
Orbitrap mass spectrometer. From each full-scan spectrum, the 15 ions with the 
highest intensity were selected for fragmentation in the ion trap. A lock-mass 
correction with a background ion (mass/charge ratio, 445.12003) was applied. 
2.2.5.3. Bioinformatic analysis of proteomic data 
MS raw data files were processed with Bioconductor using the packages:  Biobase, 
BiocGenerics, and Parallel. Contaminants and reverse sequences were removed. 
The peptides were mapped to the Uniprot database. Using the protein identifier, the 
peptides were mapped to the associated ensembl genes as reported by Uniprot. For 
each ensembl gene id a generic protein was selected. Among all proteins that cover 
most peptides, the longest was selected. Peptides not mapping to the longest protein 
were not considered in the sequel analysis.  
The samples were labelled as follows with a label swap between the two technical 
replicates. All biological replicates were labelled the same.  
Mouse: 
Technical replicate a Technical replicate b 
Cpa3Cre/+ PEC Heavy Cpa3Cre/+ Light 
Cpa3+/+ sorted MC Light Cpa3+/+ sorted MC Heavy 
Cpa3+/+ PEC Medium Cpa3+/+ PEC Medium 
 
Human: 
Technical replicate a Technical replicate b 
Skin MC Heavy Skin MC Light 
Fat MC Light Fat MC Heavy 
PBMC Medium PBMC Medium 
 
Peptide intensities of 0 were interpreted as missing values and therefore replaced by 
NA. The expression data was normalized using the variance stabilising normalization 
(Huber et al., 2002). Computing the mean summarized the technical replicates. For 
statistical analysis of the comparisons (e.g. Skin MC/PMBC), the peptide intensities 
in the two conditions were subtracted from each other. The peptide log-ratios are 
averaged for each protein. The p-value was computed by a moderated t-test as 
implemented in the R/Bioconductor package limma (Lönnstedt and Speed; Smyth, 
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2004). p-values were corrected for multiple testing by the method of Benjamini-
Hochberg (Benjamini and Hochberg, 1995). 
Enrichment of gene sets was analysed for all genes that were up- (down-) regulated 
in mast cells. Redundant mouse mast cell enriched gene sets were reduced and 
summarized using REVIGO (Supek et al., 2011). 
2.2.5.4. Antibody clean-up and labelling 
Commercially available antibodies often contain BSA for stabilization of low 
concentrated antibody solutions, which interferes with downstream antibody labelling. 
Anti-CD63 antibody (Clone NVG-2) was purchased from Biolegend. BSA was 
removed from the antibody solution using the Pierce™ Antibody Clean-up Kit 
according to the manufacturers instructions. AlexaFluor647, pHrodoRed, or Biotin 
was conjugated to hCD4 (TNX355), NVG-2 (mCD63), and H5C5 (hCD63). Briefly, 
amine reactive AlexaFluor647, pHrodoRed or Biotin was mixed with 100 ug of 
antibody (10X molar excess) in 0.1 M sodium bicarbonate buffer, and incubated for 
60 minutes at RT in the dark. Subsequently unbound dye was removed by size 
exclusion using either the supplied purification resin or Zeba™ Spin desalting 
columns. 
2.2.5.5. Biotin quantitation 
The degree of biotin labelling was determined using the Pierce™ Fluorescence Biotin 
Quantitation Kit. Briefly, the Thermo Scientific DyLight Reporter (i.e., fluorescent 
avidin and HABA premix) was added to the biotinylated antibodies and diluted 
biocytin standards. HABA (4'-hydroxyazobenzene-2-carboxylic acid) binds weakly to 
the fluorescent avidin, thereby quenching the fluorescent signal. When the HABA is 
displaced by biotin in the test sample, fluorescence can be measured with a 
fluorescence plate reader (excitation 494 nm; emission 520 nm). The amount of 
fluorescence in the sample is determined by comparing the fluorescence to the 
standard curve. The antibody concentration was determined by measuring the 
absorbance of the antibody solution at 280 nm with a UV-VIS Spectrophotometer 
(NanoDrop2000). The molar concentration was calculated using an extinction 
coefficient of 230.000 M-1 cm-1 (Maity et al., 2015). 
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3. Results 
3.1. Anti-hCD4-mediated mast cell ablation 
The aim of this work was to label and eliminate mast cells by monoclonal antibodies. 
For this, I sought to establish an in vivo mast cell ablation strategy. To date, there is a 
lack of information on mast cell specific cell surface receptors that may be used for 
targeting of mast cells with mAbs. In order to avoid difficulties with unspecific mast 
cell markers we first sought to establish antibody-dependent mast cell ablation by 
using a model antigen. Thorsten Feyerabend, in the Rodewald laboratory, previously 
developed an animal that expresses an ectopic antigen specifically in mast cells. In 
this Cpa3hCD4 mouse model, a modified human CD4 receptor was introduced into the 
mast cell specific Cpa3 locus by gene targeting (Feyerabend, 2007). This hCD4 
molecule lacks intracellular signalling domains to exclude signalling dependent 
receptor internalization, and thus increase surface exposition of the receptor for 
enhanced sensitivity in flow cytometric analysis. hCD4 was chosen since a variety of 
commercially available antibodies specific for this receptor are available, yet its 
sequence is differential to any other mouse proteins, providing high specificity and 
low staining background. 
This model system was used towards establishment of systemic mast cell ablation 
after anti-hCD4 antibody administration. Once established, we aim to transfer the 
ablation conditions to physiological mast cell antigens that I identified in parallel. 
3.1.1. Characterisation of Cpa3hCD4  
Ear skin, tongue, fat, stomach and peritoneal cells were stained with antibodies 
specific F4/80, CD45, CD117 and IgE. Phenotypic mast cells (F4/80- CD45+ CD117+ 
IgE+) were found in all tissues. There is no difference in mast cell numbers between 
Cpa3+/+ and Cpa3hCD4/+ mice. It has been previously shown that homozygous knockin 
into the Cpa3 locus, such as in Cpa3hCD4/hCD4 (Cpa3 knockout) does not have an 
influence on the number of mast cells (Feyerabend et al., 2005). 
In the C57BL/6 strain background more mast cells could be found in the skin, tongue, 
fat and peritoneaal cavity, while BALB/c mice had slightly more mast cells in the 
stomach (Figure 4). 
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Figure 4: Absolute number of mast cells in Cpa3hCD4/+ knockin mice 
Skin, tongue, fat, stomach and peritoneal exudate cells from BALB/c Cpa3+/+, BALB/c 
Cpa3hCD4/+, C57BL/6 Cpa3+/+ and C57BL/6 Cpa3hCD4/+ mice were analysed by flow 
cytometry for the presence of CD45+ CD117+ IgE+ mast cells. Shown are the mean ± 
SEM for three animals per genotype. (*p < 0.05, **p < 0.01). 
 
 
In order to assess specificity and intensity of hCD4 expression, the mean 
fluorescence intensity (MFI) of the hCD4 staining was determined for different cell 
populations. By gating on live (Sytox blue-) CD45+ CD117+ IgE+ cells the hCD4 
expression level of mast cells from different organs was compared. Specificity of 
hCD4 expression was determined by comparing the fluorescence intensity signals of 
different mast cell compartments to splenic B cells, T cells, basophils, eosinophils, 
neutrophils, and monocytes. We found hCD4 expression almost exclusively restricted 
to mast cells. All tested tissue mast cells in Cpa3hCD4 mice expressed hCD4 to a 
similar extent with the exception of peritoneal mast cells that displayed 3-4 fold 
higher MFI (Figure 5). Only basophils, which share a close lineage relationship with 
mast cells, stained weakly positive for hCD4. 
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Figure 5: Mast cell specific cell surface expression of hCD4 in Cpa3hCD4/+ knockin mice 
Mast cells (CD45+ CD117+ IgE+) from skin, tongue, fat and stomach cells were 
analysed by flow cytometry for intensity of hCD4 expression. Specificity was 
demonstrated by comparing peritoneal mast cells to B cells (CD19+), T cells (CD3+), 
basophils (CD49b+ IgE+), eosinophils (SSChi Siglec-F+), neutrophils (CD11b+ Gr-1+) 
and monocytes (CD11b+ F4/80+) from spleens of BALB/c Cpa3+/+, BALB/c 
Cpa3hCD4/+, C57BL/6 Cpa3+/+ and C57BL/6 Cpa3hCD4/+ mice. Shown are the mean ± 
SEM of three animals per genotype pooled from 3 individual experiments.  
 
Measurement of the hCD4 MFI implied differential expression levels of hCD4 on 
different peripheral mast cell compartments. More likely, however, would be the 
possibility of partial antigen loss during collagenase digestion for organ dissociation. 
To test the influence of collagenase treatment on hCD4 surface expression, I 
incubated peritoneal mast cells with and without 1 mg/ml Collagenase 8. hCD4 
expression was approximately 10-fold lower on collagenase-treated peritoneal mast 
cells compared to untreated mast cells (Figure 6). In addition, it could be observed 
that CD117 cell surface expression was also reduced by collagenase digestion. 
 
 
Sk
in
To
ng
ue Fa
t
St
om
ac
h
0
2000
4000
6000
8000
hC
D
4 
M
FI
 
Pe
rit
on
ea
l C
av
ity
B 
ce
lls
T c
ell
s
Ba
so
ph
ils
Eo
sin
op
hil
s
Ne
utr
op
hil
s
Mo
no
cy
tes
0
2000
4000
10000
20000
30000 BALB/c Cpa3+/+
BALB/c Cpa3hCD4/+
C57BL/6 Cpa3+/+
C57BL/6 Cpa3hCD4/+
Results 
 40 
 
Figure 6: Receptor cleavage by collagenase treatment 
Peritoneal cells from C57BL/6 Cpa3hCD4/+ mice were untreated (left) or incubated with 
1 mg/ml collagenase 8 for 30 minutes at 37°C (middle). Cells were analysed by flow 
cytometry for binding of anti-hCD4 antibody (right). On the histograms, collagenase 
8-treated mast cells are depicted in blue, untreated mast cells are depicted in red.  
 
In summary, hCD4 is, with high specificity, strongly expressed in the mast cell 
lineage. Mast cell numbers are not affected by the gene knockin or transgene 
expression. Therefore the Cpa3hCD4 mouse is a suitable tool for establishing ADCC-
mediated targeting protocols. 
3.1.2. Characterisation of TNX355 (anti-hCD4) antibody 
The TNX355 antibody (also known as Ibalizumab or TMB-355) is a monoclonal 
antibody against human CD4 with a mouse IgG2a isotype. The antibody was first 
developed by Tanox, now part of Genentech and was developed to inhibit cellular 
entry of HIV. Our collaborator Medimmune has generously provided it to us for 
experimental usage. 
It has been shown by Nimmerjahn and colleagues that in mice the isotype IgG2a and 
the FcγRI and FcγRIV receptors are crucial for initiating antibody dependent cell-
mediated cytotoxicity (ADCC). Moreover, binding strength between IgG2a and FcγRI 
or FcγRIV could strongly be enhanced by removal of the core fucose from the N-
linked glycosylation of the IgG Fc portion (Nimmerjahn, 2005). In our experiments we 
also used an afucosylated TNX355 antibody (kindly provided by MedImmune) that 
was generated in a chinese hamster ovary cell line lacking the gene for the 
fucosyltransferase Fut1. 
FACS analysis of peritoneal mast cells showed that both TNX355 and the 
afucosylated TNX355 variant bind to the hCD4 antigen on the surface of mast cells of 
C57BL/6 Cpa3hCD4/+ mice.  
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Figure 7: TNX355 binds hCD4 expressing mast cells in Cpa3hCD4/+ knockin mice 
Peritoneal exudate cells from C57BL/6 Cpa3hCD4/+ mice were stained with either 
isotype mouse antibody (IgG2a) or TNX355 or afucosylated TNX355 antibody. Cell 
surface bound mouse IgG2a antibody was detected by an anti-IgG2a secondary 
antibody. A representative FACS plot of live mast cells (Sytox-blue- CD117+) (left) 
and anti-IgG2a staining is shown (right). 
 
3.1.3. In vivo ablation of hCD4+ mast cells 
Next, I wanted to investigate the in-vivo mast cell ablation capabilities of the TNX355 
antibody in the Cpa3hCD4 mouse model. C57BL/6 Cpa3hCD4/hCD4 or BALB/c Cpa3hCD4/+ 
mice were treated intravenously with one dose of 300 µg TNX355 (Figure 8), 4 doses 
of 300 µg TNX355 (Figure 9), 3 doses of 900 µg TNX355 (Figure 10), or 3 doses of 
900 µg afucosylated TNX355. Mice on C57BL/6 and BALB/c strain backgrounds 
were used interchangably, due to availability. In experiments with multiple dosing, 
injections were performed on alternating days. Seven days after the last injection, 
mice were sacrificed and mast cell depletion was analysed by flow cytometry. 
 
A single injection of 300 µg of TNX355 antibody resulted in a reduction of peritoneal 
mast cells to about 50% (Figure 8). However, no reduction could be observed for 
stomach, skin, fat and tongue tissue mast cells. 
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Figure 8: Mast cell depletion with a single dose of TNX355 treatment 
C57BL/6 Cpa3hCD4/hCD4 mice were treated i.v. with 300 µg of TNX355 or isotype 
control antibody. Seven days later, mice were sacrificed and organs were isolated for 
subsequent flow cytometric evaluation of mast cell ablation. a) The number of 
phenotypic mast cells per 105 CD45+ cells in different organs is shown. The number 
of total CD45+ cells remained constant for each indicated organ. Mean ± SEM for two 
to three animals per treatment group. b) Representative FACS plots of the different 
mast cell compartments. Numbers indicate percentages of mast cells within the live 
F4/80- CD45+ gate.  
 
 
Scholten and colleagues developed a mouse model of diphtheria toxin-dependent 
mast cell ablation by crossing their Mcpt5-Cre transgenic mouse strain to a floxed 
iDTR mouse strain. With this inducible model they observed that repetitive dosing of 
diphtheria toxin enhanced the depletion of mast cells in peripheral tissues (Julia 
Scholten, 2009). To test whether multiple doses of TNX355 antibody would also 
enhance ADCC-mediated mast cell ablation, we repetitively injected our mice in the 
following experiments. First we gave 4 x 300µg of TNX355 or isotype control 
antibody intravenously to BALB/c Cpa3hCD4/+ mice.  
 
Four injections with a total dose of 1.2 mg of TNX355 antibody resulted in a strong 
peritoneal mast cell depletion. There was also depletion of stomach mast cells 
(Figure 9). However, no mast cell ablation could be detected in skin, fat and tongue 
tissue. In the isotype treated animals a marked influx of CD45+ cells into the tongue 
could be observed. This influx resulted in lower relative mast cell numbers (MC/105 
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CD45+ cells), which accounts for the comparatively increased number of mast cells in 
tongue tissue (Figure 9a).  
 
 
Figure 9: Mast cell depletion with multi-dose TNX355 treatment 
BALB/c Cpa3hCD4/+ mice were treated with a maximum dose of 1.2 mg of TNX355 or 
isotype control antibody. Seven days after the last injection, mice were sacrificed and 
organs were isolated for subsequent flow cytometric evaluation of mast cell numbers. 
a) The number of phenotypic mast cells per 105 CD45+ cells in different organs is 
shown. Mean ± SEM for two to three animals per treatment group. b) Representative 
FACS plots of the different mast cell compartments. Numbers indicate percentages 
of mast cells within the live F4/80- CD45+ gate. 
 
An adult C57BL/6 mouse of 25 g has approximately 1.6 ml blood and a haematocrit 
of 42% (GV-SOLAS). At an average IgG serum concentration of 2-5 mg/ml (Sigma-
Aldrich) this translates into a total amount of circulating mouse IgG of 1.9 – 4.6 mg. 
To determine the maximal feasible depletion efficacy in our experimental model we 
injected 3 x 900 µg of TNX355 or isotype control antibody intravenously into C57BL/6 
Cpa3hCD4/hCD4 mice. This dose corresponds to half of the mouse’s endogenous IgG.  
Three injections with a total dose of 2.7 mg of TNX355 antibody resulted in near 
complete depletion of peritoneal and stomach mast cells (Figure 10). With this dose 
we were able to receive a small reduction in fat mast cells however no ablation of 
skin and tongue mast cells could be observed. As before, a marked influx of CD45+ 
cells into the tongue resulted in skewing of TNX355 treated tongue mast cell 
quantification (Figure 10a). 
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Figure 10: Mast cell depletion with maximal dose escalation 
C57BL/6 Cpa3hCD4/hCD4 mice were treated with a total dose of 2.7 mg of TNX355 or 
isotype control antibody. 7 days after the last injection mice were sacrificed and 
organs were isolated for subsequent flow cytometric evaluation of mast cell ablation. 
a) The number of phenotypic mast cells per 105 CD45+ cells in different organs is 
shown. Mean ± SEM for two to three animals per treatment group. b) Representative 
FACS plots of the different mast cell compartments. Numbers indicate percentages 
of mast cells within the live F4/80- CD45+ gate. 
 
To further increase the depletion efficiency without increasing the antibody dose, we 
investigated the depletion efficiency of the afucosylated TNX355 variant. 
Afucosylation has been previously shown to enhance ADCC in vivo (Nimmerjahn, 
2005). In this experiment we injected 3 x 900 µg of afucosylated TNX355 or isotype 
control antibody intravenously into C57BL/6 Cpa3hCD4/hCD4 mice. A total dose of 2.7 
mg of afucosylated TNX355 antibody resulted in near complete depletion of 
peritoneal and stomach mast cells (Figure 11). As in the previous experiments, a 
small reduction in fat mast cells, but no reduction in skin and tongue mast cells was 
observed. 
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Figure 11: Mast cell depletion by treatment with afucosylated TNX355 
C57BL/6 Cpa3hCD4/hCD4 mice were treated 3x on alternating days i.v. with 900 µg of 
afucosylated TNX355 or afucosylated isotype control antibody in 200 µl of PBS. 7 
days after the last injection mice were sacrificed and organs were isolated for 
subsequent flow cytometric evaluation of mast cell ablation. a) The number of 
phenotypic mast cells per 105 CD45+ cells in different organs is shown. Mean ± SEM 
for two to three animals per treatment group. b) Representative FACS plots of the 
different mast cell compartments. Numbers indicate percentages of mast cells within 
the live, F4/80-, CD45+ gate. 
 
 
In summary, we demonstrated that mast cells, in principle, can be depleted by an 
antibody dependent cytotoxicity mechanism. Mast cell ablation was different for 
individual organs. The degree of mast cell ablation in the Cpa3hCD4 model was 
correlated to the injected antibody dose. Mast cells of the peritoneal cavity and the 
stomach were most sensitive while mast cells from ear skin, fat, and tongue were 
refractory. In contrast to the literature, we were not able to further increase the 
ablation efficiency by using a glyco-engineered antibody.  
3.1.4. Bio-distribution of TNX355 in vivo 
Previously it has been shown that blood vessels form a semi-permeable barrier that, 
under non-inflammatory conditions, restricts the traffic across the endothelium for 
molecules larger than 70 kDa (Egawa et al., 2013). For monoclonal antibodies with 
sizes of ~150 kDa the main mechanism of transport from blood to the interstitium was 
shown to be convection (i.e. diffusion along a concentration gradient). The rate of 
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mAb convection is determined by the antibody concentration and by degree of 
endothelial fenestration (Wang et al., 2008). 
To test whether insufficient transendothelial passage was responsible for the 
observed lack of mast cell depletion in the skin, tongue, and fat I labelled TNX355 
and isotype control antibody with AlexaFluor-647 (A647). I intravenously injected 
100 µg of either of the two antibodies into C57BL/6 Cpa3hCD4/hCD4 mice. Mast cells 
were isolated 48 hours later from the different organs and tested for in situ bound 
antibody by flow cytometric analysis (Figure 12). 
 
Figure 12: In situ labelling of mast cells by fluorescent coupled TNX355 
C57BL/6 Cpa3hCD4/hCD4 mice were intravenously injected with 100µg of A647 labelled 
TNX355 or isotype control antibody. Mice were sacrificed 48 hours later and organs 
were isolated for subsequent flow cytometric evaluation of in vivo mast cell labelling. 
a) Histograms are pre-gated for mast cells (live, CD45+, F4/80-, CD117+ FcεRI+) and 
depict prior binding of the antibodies TNX355-A647 (red) or isotype control (black). b) 
The A647 mean fluorescence intensity of the different mast cell compartments is 
shown. Mean ± SEM for two animals per treatment group. 
 
Interestingly, mast cells in all analysed tissues were labelled by TNX355 to similar 
extent. There was no difference in antibody binding between tissue mast cells and 
peritoneal mast cells. Therefore, mechanisms other than TNX355 antibody 
bioavailability or binding in tissues seem to account for the lack of ADDC-dependent 
mast cell depletion observed in the skin, tongue and fat tissue. 
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3.1.5. Passive systemic anaphylaxis assay 
In order to test, whether the partial ablation of mast cells, i.e. their ablation in 
stomach and peritoneal cavity, already translates into a physiologically measurable 
phenotype, TNX355 treated mice were subjected to IgE-mediated anaphylaxis. The 
principle of this assay is to first passively load and sensitize mast cells with antigen-
specific IgE, and then to induce mast cell degranulation via crosslinking of the FcεRI-
bound IgE by injecting multivalent antigen. Subsequent release of bioactive amines, 
such as histamine and serotonin induces vascular permeabilization and smooth 
muscle contraction. Since both IgE and antigen are supplied systemically, mast cells 
throughout the body may respond, leading to systemic anaphylaxis. Subsequently, 
dramatic patophysiological reactions occur, e.g. the blood pressure, after a short 
transient raise, drops dramatically and hypothermia sets in. We used this decline of 
the body temperature to monitor anaphylaxis via mast cell activation. 
 
 
Figure 13: Passive systemic anaphylaxis in mast cell-depleted mice 
C57BL/6 Cpa3hCD4/hCD4 mice that received 2.7mg of afucosylated TNX355 for mast 
cell depletion or that were injected with isotype antibody were subjected to passive 
systemic anaphylaxis. Genetically mast cell-deficient Cpa3Cre/+ mice were used as a 
positive control for the absence of mast cells. All mice were injected i.v. with 20 µg 
anti-DNP IgE and challenged on the subsequent day by i.v. injection of 20 µg DNP15-
Ovalbumin. The anaphylactic response was monitored by determining the change of 
body temperature. Rectal temperatures were measured in 10 min intervals and are 
expressed as temperature difference (ΔT) compared to baseline temperature. The 
mean ± SEM for two to four animals per treatment group is shown.  
 
As expected, strong hypothermia was observed in mice that were not mast cell 
depleted, but had received the isotype control antibody. Genetically mast cell-
deficient Cpa3Cre/+ mice did not show any change in body temperature, thus were 
resistant to anaphylaxis (Feyerabend et al., 2011). However, mice that had received 
the TNX355 treatment displayed the same temperature drop seen in control depleted 
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and Cpa3hCD4/hCD4 mice. Hence, ablation of peritoneal and stomach mast cells is not 
sufficient to prevent anaphylaxis induced hypothermia. 
3.2. Mast cell proteomics 
To our knowledge there is currently no comprehensive mass-spectrometric (MS) 
dataset of primary mouse or human mast cells available. Such experiments however, 
would be very useful for the identification of key pathways and novel functions of 
mast cells, and the identification of novel mast cell-specific drug targets. Due to the 
very low abundance of mast cells in tissues, isolating large quantities of cells 
normally required for mass-spectrometry is difficult, and therefore most researchers 
instead focused on mRNA-expression analysis. However, for a functional analysis of 
mast cells the determination of protein expression on a global scale would be more 
meaningful. 
The isolation of primary mouse mast cells is well established in our laboratory, and 
by using peritoneal cells as a source the need for enzymatic tissue digestion for mast 
cell isolation can be avoided. For these reasons, murine peritoneal mast cells are 
ideal starting material for the establishment of protein extraction and sample 
preparation for subsequent quantitative mass spectrometry.  
 
3.2.1. Mouse peritoneal mast cell proteomics 
Different strategies have been successfully employed to identify cell surface 
receptors of a variety of cells. To investigate the membrane proteome, and thereby 
cell surface receptors, researchers have relied on two main strategies. Traditionally, 
density gradient separation was used to separate the membrane fraction from the 
organelle and nuclear proteins. In the recent years, biotin or lectin labelling 
approaches have been successfully developed to label and capture cell surface 
proteins (Elia, 2008; Elschenbroich et al., 2010; Vuckovic et al., 2013). However, all 
of these biochemical approaches demand extremely large cell numbers, which is 
compatible with immortalized cell lines but often impossible with primary cells. 
Because numbers of primary mast cells remains limiting, we opted for whole 
proteome analysis without prior enrichment for membrane proteins.  
As we are primarily interested in mast cell specific cell surface proteins, the isolation 
of mast cells from the peritoneal lavage, obtained without enzymatic tissue digestion 
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is advantageous. In this way, the extracellular domains of cell surface proteins are 
protected from cleavage by digestion enzymes. 
 
The peritoneal lavage of C57BL/6 wild type mice contains about 2-4 mio. cells of 
which approximately 1-3% are mast cells. With positive magnetic bead selection for 
CD117+ cells, mast cells could be enrichment to 40 - 60 %. For purity of more than 
96% cells were sorted on a BD FACSAria cell sorter (Figure 14). In our hands, 
approximately 5000-10000 peritoneal mast cells could be isolated from a single 6-8 
week old C57BL/6 wild type mouse.  
Apart from C57BL/6 wild type peritoneal cells and sorted mast cells we chose to 
include peritoneal cells from C57BL/6 Cpa3Cre/+ mice that are genetically mast cell-
deficient and thus serve as an optimal negative control. 
 
 
Figure 14: Isolation, enrichment and purification of mast cells for proteome 
analysis 
Peritoneal cells of C57BL/6 Cpa3+/+ and C57BL/6 Cpa3Cre/+ mice were isolated by 
peritoneal lavage. Mast cells of C57BL/6 Cpa3+/+ were enriched by two-step 
purification. First, CD117+ cells were selected by magnetic beads and subsequently 
phenotypic mast cells (live, CD45+, F4/80-, CD117+ FcεRI+) were sorted on a BD 
FACSAria cell sorter. Representative FACS plots of the consecutive mast cell 
enrichment steps are shown. Samples used for proteomics are highlighted in red. 
Numbers indicate percentages of cells in each quadrant. 
 
In collaboration with Mandy Rettel at the EMBL proteomics core facility we subjected 
three different cell populations (Figure 14) to quantitative mass spectrometry (MS). 
We chose total Cpa3+/+ peritoneal cells (including 1-3% mast cells), sorted mast cells 
(purities higher than 96%), and total Cpa3Cre/+ peritoneal cells (lacking mast cells).  
The three cell populations were digested with trypsin and then labelled with different, 
stable dimethyl isotopes. For each MS run, tryptic peptides from 50.000 cells of each 
population were mixed in a 1:1:1 ratio and run on a high pH HPLC. Subsequently, the 
collected fractions were analysed by low pH HPLC-coupled MS/MS. Because three 
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differentially labelled populations were analysed in parallel, the peptide intensities 
can be relatively quantified.  
 
In collaboration with Dr. Bernd Fischer, from the computational genome biology 
group at Dkfz, we performed detailed bioinformatics analysis on the proteomic 
dataset. From the raw data, a total of 45396 peptides were identified. The peptides 
were then mapped to proteins in the uniprot database. Due to repetitive protein 
motives and sequence similarities, some peptides mapped to multiple proteins or 
splice variants. In order to quantify such peptides, protein groups were created to 
determine the coverage of a certain protein. Proteins were then mapped to genes in 
the Ensembl database. For each gene the highest-covered corresponding protein 
was chosen. 
Some peptides could not be mapped to a unique protein group (non-unique protein 
group). Some peptides that mapped to a protein in the uniprot database could not be 
mapped because of missing entries in the Ensembl database (no gene). Some 
peptides mapped to a single protein and gene, however the peptide did not belong to 
the highest-covered protein (Not on largest group). Peptides that could not be 
mapped were excluded from further analysis. The unique peptides cover 5459 
different genes (Figure 15).  
 
 
Figure 15: Mouse mast cell proteomics and peptide mapping 
a) 45396 peptides were identified in three independent biological replicates (BR1-3). 
Peptides were mapped to the Uniprot protein database. 444 Proteins mapped to no 
gene. 2915 peptides mapped to non-unique protein group and 1289 peptides did not 
map to their highest-covered proteins. The remaining 40748 peptides were mapped 
to their corresponding genes.  
b) The histogram depicts the uniqueness of the peptide mapping. The x-axis shows 
the number of genes a peptide maps to. The y-axis shows the number of peptides 
that map to as many genes. 
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The number of measured peptides and the number of identified proteins is within the 
range of a typical proteomics experiment. The correlation among the biological 
replicates exceeds 0.6 for all replicates, indicating a high quality of the dataset. 
 
  Low 1% FDR Low 10% FDR unchanged High 10% FDR High 1% FDR 
MC / Cpa3Cre/+ 46 485 2717 408 98 
MC / Cpa3+/+ 32 419 2807 385 90 
 
Table 2: Number of proteins differentially expressed in mouse mast cells 
compared to peritoneal exudate cells 
Listed is the number of proteins being at least 2-fold higher (red) or lower (blue) 
expressed in mast cells compared to total peritoneal exudate cells with false 
discovery rate (FDR) of 1% or 10%. FDR is a statistical tool used for the analysis of 
large datasets to correct error from multiple testing. 1%/10% FDR introduces a 
threshold for normally distributed p-values in which either 99% or 90% of results are 
predicted to be correct (Benjamini and Hochberg, 1995). 
 
The majority of proteins quantified in this proteomics screen (72%/75%) were 
unchanged in the comparison of sorted mast cells / Cpa3Cre/+ PEC as well as in the 
sorted mast cells / Cpa3+/+ PEC comparison. The number of proteins that are less 
expressed in mast cells is slightly higher than the proteins that are higher expressed. 
 
Next, we looked closer at the data with the help of a volcano plot to display large 
magnitude changes (Figure 16). 
 
 
Figure 16: Depiction of differential protein expression of mouse mast cells 
versus peritoneal cells 
Volcano plots presenting differential protein expression of sorted mast cells a) 
compared to Cpa3Cre/+ PEC and b) compared to wild type PEC (x-axis) and its 
respective significances (y-axis). Proteins with 2-fold expression change (employing 
1% FDR) are either coloured in red (highly expressed) or blue (low expressed). 
Results 
 52 
Typical mast cell markers identified with this screen are marked by arrows and 
indicated with their names. 
 
The well-established mast cell markers Carboxypeptidase A3 (Cpa3), Chymase 1 
(Cma1), and stem cell factor receptor Kit (Kit) were found among the proteins that 
were most strongly expressed in mast cells, which measures the validity of the 
dataset to identify mast cell specific proteins. 
Previous studies have shown strong differences in mast cell related mRNA 
expression, when comparing whole tissue RNA preparations (skin) of mast cell 
sufficient Cpa3+/+ and mast cell deficient Cpa3Cre/+ mice (Feyerabend et al., 2011). 
However, the proteomic comparison of whole PEC of Cpa3+/+ and Cpa3Cre/+ mice in 
our experiment is not informative as the comparison shows minimal difference in 
mast cell specific protein expression. It is probable that this discrepancy results from 
the limit of detection in mass spectrometry experiments. 
We therefore focussed our further analysis on the sorted MC vs. PEC comparisons. 
In that regard it appears that the MC / Cpa3Cre/+ comparison is more sensitive than 
the MC / Cpa3+/+ comparison in detecting mast cell specific proteins as there are 
more proteins detected (Table 2). For that reason, we are focussing on the 
comparison of sorted mast cells vs. Cpa3Cre/+ PEC for our subsequent analysis. 
 
Having shown that the mast cell proteome dataset is valid to identify mast cell 
specific proteins, we sought to determine whether the dataset could also be used to 
identify mast cell specific functional pathways. 
3.2.2. Gene ontology analysis of the mouse mast cell proteome 
Gene ontology analysis enables the functional interpretation of experimental data by 
classification of genes into defined categories. Here, we performed gene ontology 
enrichment analysis to gain information about mast cell enriched processes and 
functions (Figure 17). 
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Figure 17: Proteome analysis based on mouse Gene Onthology (GO) analysis 
for the term ‘Cellular Component’ 
Shown are Gene Ontology terms for the category ‘Cellular Component’ based on 
mast cell enriched proteins depicted as OddsRatio in log scale. 
 
The mast cell enriched GO terms in the category ‘Cellular Component’ can be 
divided into 5 groups. Plasma membrane associated (trans membrane, cell surface 
and membrane associated proteins); Vesicular compartment (vacuolar, lysosomal 
and granular proteins); Extracellular (secreted proteins); Cellular extension (synaptic, 
and membrane projection proteins); and Others.  
 
The GO analysis of ‘Cellular Component’ reveals that the group Vesicular 
compartment is the biggest group represented, indicating that many vesicular 
proteins, likely also mast cell granule proteins, are enriched in this dataset.  
Next, we were interested whether we can conclude unique mast cell functions based 
on the GO analysis of the term ‘Biological Process‘ (Figure 18). 
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Figure 18: Proteome analysis based on mouse GO analysis for the term 
‘Biological Process‘ 
Shown are Gene-Ontology terms for the category ‘Biological Process‘ based on mast 
cell enriched proteins depicted as OddsRatio (log scale). 
 
The mast cell enriched GO terms in the category ‘Biological Process’ can be 
subdivided into 4 groups: transport and secretion; metabolic process; response to 
environment; and others. Interestingly, the two most prominent features that are 
highly enriched in this analysis are serotonin transport and glucosamine metabolism, 
both of which are known integral functions of mast cells. This analysis underscores 
the uniqueness of mast cells among hematopoietic cells to synthesize bioactive 
amines and proteoglycans. 
3.2.3. The most abundant proteins of murine mast cells 
In order to identify novel characteristic / unique mast cell marker proteins, proteomics 
data were listed by fold change and their p-values that were optimized for multiple 
testing (p.adjusted). All three populations were measured in parallel, thus the fold 
change describes the abundance of a certain protein in a sample over the 
abundance of the same protein in a second sample. 
Below, I depict in detail the top 20 differentially expressed proteins with significant 
fold change in sorted mast cells over Cpa3Cre/+ PEC.  
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ProtID	 Symbol	 Protein	name	 log2FC	 pvalue	 padjusted	rep1	 rep2	 rep3	
Q91XV3	 Basp1	 Brain	acid	soluble	protein	1	 8.260	 1.37E-06	 0.00148	 8.387	 9.110	 7.282	
P15089	 Cpa3	 Carboxypeptidase	A3	 7.756	 3.37E-06	 0.00148	 8.065	 8.663	 6.541	
P21812	 Mcpt4	 Mast	cell	protease	4	 6.881	 1.84E-06	 0.00148	 7.371	 7.117	 6.154	
Q8CB87	 Rab44	 Ras-related	protein	Rab-44	 6.717	 3.43E-06	 0.00148	 6.338	 7.648	 6.165	
Q8BW75	Maob	 Monoamine	oxidase	type	B	 6.635	 2.39E-06	 0.00148	 5.892	 6.869	 7.143	
P21845	 Tpsb2	 Tryptase	beta-2	(mMCP6)	 6.619	 9.38E-07	 0.00148	 6.708	 6.771	 6.377	
P28293	 Ctsg	 Cathepsin-G	 6.559	 4.89E-06	 0.00148	 5.745	 6.436	 7.496	
P41731	 CD63	 Tetraspanin	 6.469	 5.52E-06	 0.00148	 7.349	 5.558	 6.499	
Q60963	 Pla2g7	 Platelet-activating	factor	acetylhydrolase	 6.351	 4.15E-06	 0.00148	 6.634	 6.928	 5.489	
P14719	 Il1rl1	 IL-33	receptor	 5.641	 4.51E-06	 0.00148	 5.377	 6.250	 5.296	
P70665	 Siae	 Sialate	O-acetylesterase	 5.216	 6.39E-06	 0.00148	 5.592	 5.381	 4.675	
P07309	 Ttr	 Transthyretin	 5.140	 4.34E-06	 0.00148	 5.246	 5.287	 4.885	
Q08642	 Padi2	 Protein-arginine	deiminase	type-2	 5.038	 5.80E-06	 0.00148	 5.066	 5.356	 4.693	
Q9JIM1	 Slc29a1	 Equilibrative	nucleoside	transporter	1	 5.033	 6.78E-06	 0.00148	 4.745	 4.852	 5.503	
Q9Z127	 Slc7a5	 Large	neutral	amino	acids	transporter	small	subunit	1	 4.873	 5.64E-06	 0.00148	 4.908	 5.023	 4.687	
Q3UW53	 Fam129a	 Protein	Niban	 4.744	 6.99E-06	 0.00148	 4.986	 4.689	 4.556	
P51576	 P2rx1	 P2X	purinoceptor	1	 4.532	 8.08E-06	 0.00162	 4.492	 4.493	 4.612	
Q80UR4	 Prss34	 Mast	cell	protease-11	 5.867	 1.07E-05	 0.00193	 5.802	 6.819	 4.978	
Q99M71	 Epdr1	 Mammalian	ependymin-related	protein	1	 5.191	 1.03E-05	 0.00193	 5.835	 5.216	 4.522	
P29387	 Gnb4	 Guanine	nucleotide-binding	protein	subunit	beta-4	 4.493	 1.18E-05	 0.00203	 4.863	 4.172	 4.444	
Table 3: Top 20 proteins (sorted mast cell vs. Cpa3Cre/+ PEC) 
Shown are the top 20 protein expression values of sorted mast cells / Cpa3Cre/+ PEC. 
Log2FC is the fold change depicted as log 2; pvalue depicts the significance 
calculated by t-test; P.adjusted is the p-value corrected for multiple testing with a 
FDR of 0.05; rep stands for biological replicates. 
 
Five of the 20 proteins most strongly expressed in mast cells are known mast cell 
proteases (Cpa3, Mcpt4, Tpsb2, Ctsg and Prss34). The top scored protein is brain 
acid soluble protein 1 (Basp1), which has not been described in mast cells before. 
Basp1 is mainly known to contribute to arborisation in neurons and work from a 
single paper links Basp1 expression to synapse formation in hematopoietic cells 
(Goodfellow et al., 2011). Mast cells have also been described to form degranulatory 
synapses with IgE opsonized target cells, which might be dependent on Basp1 
(Joulia et al., 2015). 
Second on the list of the top 20 mast cell proteins is the enzyme Padi2 (protein-
arginine deiminase type 2) that mediates the hydrolysis of arginine residues to 
citrulline. It has previously been shown that bone marrow derived mast cells express 
Padi2, which becomes activated after Purinoreceptor (P2x7r) ligation by extracellular 
ATP. Padi2 and citrullinated proteins are implicated in mouse models of collagen 
induced arthritis, however mast cells could not clearly be linked as the source 
(Arandjelovic et al., 2012). To our knowledge this is the first description of Padi2 to 
be highly expressed in primary mouse mast cells. 
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Apart from the mentioned proteins, we find several proteins related to known mast 
cell function among the top 20 such as Maob (metabolism of bioactive amines) and 
Pla2g7 (PAF signalling). 
 
With our proteomics screen we aimed to identify novel mast cell specific cell surface 
receptors that might be used as targets in an antibody-based ablation model. 
Therefore, the list of mast cell-enriched proteins was filtered for cell surface 
receptors. We found that automated bioinformatics-assisted annotation of cell 
surface expression was unreliable, most likely due to incomplete or erroneous 
annotation in online databases. Therefore, we sourced uniprot annotations and in 
conflicting cases conducted a literature search to manually annotate cell surface 
proteins (Table 4). 
 
ProtID	 Symbol	 Protein	name	 log2FC	 pvalue	 padj.	 rep1	 rep2	 rep3	
P41731	 CD63	 Tetraspanin	30	 6.469	 5.52E-06	 0.00148	 7.349	 5.558	 6.499	
P14719	 Il1rl1	 IL-33	receptor	 5.641	 4.51E-06	 0.00148	 5.377	 6.250	 5.296	
P51576	 P2rx1	 P2X	purinoceptor	1	 4.532	 8.08E-06	 0.00162	 4.492	 4.493	 4.612	
Q60857	 Slc6a4	 Sodium-dependent	serotonin	transporter	 6.104	 1.60E-05	 0.00229	 4.875	 7.123	 6.313	
P05532	 CD117	 Stem	cell	factor	receptor	 4.385	 1.50E-05	 0.00229	 4.783	 3.985	 4.387	
P97449	 CD13	 Aminopeptidase	N	 4.066	 3.02E-05	 0.00294	 4.634	 3.636	 3.926	
P10852	 CD98hc	 4F2	cell-surface	antigen	heavy	chain	 3.556	 3.99E-05	 0.00327	 3.291	 3.588	 3.790	
P13595	 CD56	 Ncam1	 4.475	 5.00E-05	 0.00345	 3.582	 5.393	 4.450	
P15702	 CD43	 Leukosialin	 3.811	 4.49E-05	 0.00345	 3.209	 4.130	 4.093	
P40237	 CD82	 CD82	antigen	 3.271	 1.14E-04	 0.00498	 2.939	 3.899	 2.976	
P03958	 Ada	 Adenosine	deaminase	 3.727	 1.27E-04	 0.00525	 4.401	 2.755	 4.026	
Q5UKY4	 CD200r3	 Cell	surface	glycoprotein	OX2	receptor	3	 4.582	 1.55E-04	 0.00573	 4.282	
	
4.882	
Q9D3P8	 Plgrkt	 Plasminogen	receptor	(KT)	 4.467	 1.69E-04	 0.00615	 5.320	 2.932	 5.148	
Q08481	 CD31	 Platelet	endothelial	cell	adhesion	molecule	 4.263	 1.79E-04	 0.00629	 4.243	 4.283	
	P35762	 CD81	 Tetraspanin	 2.683	 1.93E-04	 0.00662	 2.644	 2.488	 2.917	
P53986	 Slc16a1	 Monocarboxylate	transporter	1	 2.594	 2.17E-04	 0.00712	 2.578	 2.747	 2.457	
Q9QXW9	 Slc7a8	 Large	neutral	amino	acids	transporter	small	subunit	2	 3.956	 2.58E-04	 0.00810	 		 3.941	 3.971	
Q60870	 Reep5	 Receptor	expression-enhancing	protein	5	 2.767	 2.64E-04	 0.00820	 3.294	 2.310	 2.696	
Q9Z1M0	 P2rx7	 P2X	purinoceptor	7	 2.830	 3.06E-04	 0.00866	 2.165	 3.370	 2.956	
Table 4: Top 20 mouse mast cell specific cell surface proteins 
Shown are the cell surface protein expression values of sorted mast cells / Cpa3Cre/+ 
PEC. Only proteins with a p.adjusted > 0.01 are listed. 
 
The top 20 mast cell-enriched cell surface proteins contain not only the previously 
mentioned typical mast cell markers Il1rl1 and Kit (CD117) but also several novel 
mast cell specific markers. CD117, the most important growth factor receptor for 
mast cells, binds its ligand, SCF, to promote maturation, survival and activation 
(Kawakami, 2006). Interleukin-1 receptor-like 1 (Il1rl1) binds the alarmin IL-33, which 
is released after cellular injury e.g. from epithelia (Martin and Martin, 2016). In mast 
cells, IL-33 has been shown to induce leukotriene/prostaglandin synthesis and 
cytokine release (IL-6, IL-13, TNF and others), however, there appears to be 
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differences in the response to IL-33 depending on the mast cells’ origin and species 
(Lunderius-Andersson et al., 2012). 
The enriched surface proteins can be divided into functionally distinct groups. 
Adhesion molecules constitute the largest group. Among these are CD43, CD34, 
CD56 (Ncam1) and CD31 (Pecam1). Some of these proteins have been described to 
play a role in mast cell development (CD34) but the physiological role of others has 
been less well described (Gurish and Austen, 2012). 
The group of solute carriers is the second largest group represented. Slc6a1, 
Slc16a1 and Slc7a8 (which associates with CD98) facilitate the transport of a wide 
array of substrates across the plasma membrane. Solute carriers play important roles 
in physiological processes such as nutrient, drug and xenobiotic uptake for 
downstream metabolism (Lin et al., 2015). So far, roles of these channel proteins in 
murine mast cells have not been described. 
Another prominent group of surface proteins enriched in peritoneal mast cells are 
structural components associated with transmembrane signaling receptors. CD63, 
CD81 and CD82 are representatives of the tetraspanin family. Those molecules 
cluster together with transmembrane receptors and signalling coreceptors to form 
tetraspanin-enriched micro domains (TEM), thereby assisting in signal transmission 
across the plasma membrane (Köberle et al., 2012; Levy and Shoham, 2005). CD63 
associates with FcεRI within TEMs and is required for efficient mast degranulation 
(Pols and Klumperman, 2009). CD13 (Aminopeptidase N) has only very recently 
been described to functionally interact with FcεRI and thereby to positively enhance 
degranulation (Zotz et al., 2016). 
Another small group of proteins is functionally associated with ATP metabolism. Ada 
is a membrane bound deaminase that hydrolyses adenosine to inosine, and thereby 
limits extracellular ATP signalling (inferred from Uniprot). P2 purinoreceptors bind 
extracellular ATP or ADP and become activated to channel ions and larger 
metabolites across the membrane (Wareham et al., 2009). With our proteomics 
screen we could identify P2rx1, P2rx4 and P2rx7 of which only P2rx7 shows strong 
enrichment in mast cells. P2rx7 is of special interest as it has been shown to mediate 
mast cell-dependent colon inflammation (Kurashima et al., 2012). P2rx7 also 
activates the previously mentioned Padi2 enzyme that most likely plays a role in 
arthritis development. 
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3.2.4. Verification of the most enriched mouse mast cell markers 
Having identified a variety of differentially expressed cell surface proteins in the 
proteomics dataset of peritoneal mast cells, we wanted to verify their specific surface 
expression by antibody staining. For several of the listed proteins (Table 4) 
commercial monoclonal antibodies are available. We tested by flow cytometry the 
expression of Il-1rl1, CD63, CD13 and CD98 on the different cell populations listed 
below. Antibodies against CD117 served as mast cell specific positive control (Fig. 
19). Briefly, peritoneal mast cells (F4/80- CD45+ CD117+ IgE+), macrophages (CD3- 
CD19- F4/80+), B cells (CD3- CD19+), and T cells (CD19- CD3+) as well as splenic 
basophils (CD45+ CD49b+ IgE+), eosinophils (CD45+ SSChi Siglec-F+), neutrophils 
(CD45+ Gr-1+), B cells (CD45+ CD3- CD19+), and T cells (CD45+ CD3+) of C57BL/6 
mice were stained with monoclonal antibodies, or isotype controls. 
We calculated the staining index by subtracting the mean fluorescence intensity of 
the isotype control staining from its corresponding marker antibody staining, and 
divided the result by twice the robust standard deviation of the isotype control. The 
staining index has previously been shown to be a reliable method to normalize flow 
cytometry data across experiments (Maecker et al., 2004). 
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Figure 19: Flow cytometry of the 10 most enriched mast cell receptors 
a) Il-1rl1 antibody staining of peritoneal mast cells, macrophages, B cells, and T cells 
as well as splenic basophils, eosinophils, neutrophils, B cells, and T cells of C57BL/6 
mice analysed by flow cytometry. Shown are representative histogram plots of 
isotype (black) and il-1rl1 antibody (red). b,c) Populations from (a) were tested for 
immunoreactivity against the mast cell enriched antigens il-1rl1, CD63, CD117, 
CD13, CD98 (b) or CD56, CD43, CD200r3, CD31 and CD81 (c) by flow cytometry. 
Shown is the mean of the staining index ± SEM of three animals per group. 
Results 
 60 
When staining with specific antibodies, the antigens il-1rl1, CD63, CD117, CD13, 
CD98, CD56, CD43, CD200r3, CD31 and CD81 were found to stain positive on 
peritoneal mast cells, thereby confirming the results obtained from the mass 
spectrometry based screening. While Il-1rl1 does not stain macrophages, B- and T 
cells from the peritoneal cavity, low staining intensity could be observed on basophils 
and eosinophils, which are also important cells in type 2 immune responses. 
CD63, CD117, CD13, CD200R3 and CD81 exhibited remarkable mast cell specificity, 
as negligible staining intensity could be detected on either hematopoietic cell type 
tested. While il-1rl1, CD63, CD117 and CD98 all exhibited a very high staining index 
of 20-40 on mast cells, CD13 staining was considerably lower, which might reflect 
low protein abundance or weak antibody affinity. 
CD98, CD43 and CD31 could also be detected on all other hematopoietic cell types 
tested albeit to a lower extent. Basophils exhibited the strongest staining for CD98, 
which was nearly identical to staining of mast cells. For the other hematopoietic 
subsets the staining intensity was approximately 10fold lower compared to mast 
cells.  
Apart from the top 10 presented here this experiment was also performed for the 
mast cell-enriched markers: FcεRI, CD147, CD317, CD34, CD49b, CD171, CD107a, 
P2rx7, and ß7-integrin (Supplement 2). 
These results underscore the power and reliability of proteomics-assisted biomarker 
discovery, as all of the top markers tested could be indeed verified on the surface on 
mast cells by independent flow cytometric analysis.  
 
3.2.5. Human mast cell proteomics 
For the specific characterization of human mast cells we performed an analogous 
proteomic analysis as previously established for murine mast cell samples. Human 
mast cells were isolated and purified from skin and fat tissue obtained from patients 
undergoing aesthetic surgery. 
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Figure 20: Purification of Human mast cells 
Fat (upper row) and skin tissue (lower row) from patients undergoing cosmetic 
surgery was digested, and mast cells were enriched by two-step purification. a) 
FACS plots display the enrichment along the purification protocol. Numbers indicate 
percentages of gated cells. From total digested tissue (left), CD117+ cells were 
selected by magnetic beads (middle). Mast cells were sorted for live, CD45+, CD14-, 
CD117+ FcεRI+ on a BD FACSFusion cell sorter (right).  b) Cytospins of sort- purified 
mast cells were stained with toluidine blue. 
 
For differential and quantitative comparison the following three different cell 
populations were isolated and labelled with stable dimethyl isotopes for subsequent 
mass spectrometric analyses: skin mast cells, mast cells from abdominal fat and 
peripheral blood mononuclear cells (PBMCs). PBMCs from healthy humans contain 
lymphocytes (T cells, B cells, and ILCs), monocytes, and dendritic cells and therefore 
represent a variety of immune cells but no mast cells. The frequency of those 
populations varies across individuals but is typically ~70 % T cells, ~15% B cells, 
~5% ILCs (including NK cells); ~5% monocytes and ~1% dendritic cells (Murphy et 
al., 2012). Comparing purified mast cells to a mixture of peripheral blood leukocytes, 
devoid of mature mast cells, should provide information on mast cell specific protein 
expression, and provide information on relative expression levels of the detected 
proteins. 
 
We performed three independent replicate experiments in which a total of 34483 
peptides were identified. Peptides were mapped to proteins in the uniprot database 
and the corresponding genes via alignment to the Ensembl database. A total of 4452 
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unique genes were identified. From these we could identify up to 945 proteins that 
were at least 2 fold overexpressed in human mast cells relative to PBMC (Table 5). 
 
 
Figure 21: Human mast cell proteomics and peptide mapping 
a) 34483 peptides were identified in three independent biological replicates (BR1-3). 
Peptides were mapped to the Uniprot protein database. 327 Proteins mapped to no 
gene. 2714 peptides mapped to non-unique protein group and 1 peptide did not map 
to its highest-covered protein. The remaining 31441 peptides were mapped to their 
corresponding 4452 genes.  
b) The histograms depict the uniqueness of the peptide mapping. The x-axis shows 
the number of genes a peptide maps to. The y-axis shows the number of peptides 
that map to as many genes. 
 
The measured peptide counts and the numbers of identified proteins in the human 
proteomics screen were in a comparable range, albeit slightly lower, as the data set 
obtained from murine mast cells and peritoneal cells. The frequency of peptide 
mapping to unique genes was approximately the same (90%) in both experiments.  
 
  Low 1% FDR Low 10% FDR unchanged High 10% FDR High 1% FDR 
Skin MC / PBMC 426 918 1375 945 468 
Fat MC / PBMC 516 999 1313 938 515 
Skin MC / Fat MC 1 4 3235 0 0 
Table 5: Number of proteins differentially expressed in human mast cells 
compared to peripheral blood mononuclear cells 
Listed is the number of proteins being at least 2-fold higher (red) or lower (blue) 
expressed in mast cells compared to total PBMC with false discovery rate of 1% or 
10%. 
 
Unlike the data obtained from mouse mast cells, the majority of proteins quantified in 
human mast cells were differentially expressed when comparing skin/fat mast cells to 
PBMC. The number of proteins being down regulated was similar to the number 
being up regulated. 
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In order to depict the statistically most significant differences in protein expression, 
we plotted the data of skin/fat mast cell proteome over PBMC on volcano plots 
(Figure 22). In this graph, significance is plotted against fold-change on the y and x 
axes, respectively. 
 
 
 
Figure 22:  Depiction of differential protein expression of human mast cells and 
PBMC 
Volcano plots presenting differential protein expression of a) sorted skin mast cells 
and b) sorted fat mast cells compared to PBMC (x-axis) and its respective 
significances (y-axis). Proteins with 2-fold expression change (1% FDR) are either 
coloured in red (higher expressed) or blue (lower expressed). Typical mast cell 
markers as well as novel mast cell markers, identified with this screen, are marked by 
arrows and indicated with their names. 
 
Similar to mouse mast cells, proteases such as Carboxypeptidase A3 (CPA3), 
Carboxypeptidase M (CPM), Chymase 1 (CMA1), Cathepsin G (CTSG) and the 
prototypic mast cell markers stem cell factor receptor kit (KIT) and the FcεRIγ chain 
(FCΕRIG) were found among the most up regulated proteins. We also found several, 
so far less studied, mast cell specific markers such as MAS Related GPR Family 
Member X2 (MRGPRX2), Sialic Acid Binding Ig Like Lectins 6 and 8 (SIGLEC6/8) 
and the Tetraspanins CD63 and CD82 among the highly enriched proteins. 
 
Interestingly, we found two proteins discriminating between fat and skin mast cells; 
FABP4, which is involved in lipid transport across membranes and CD36, which is a 
glycoprotein receptor for lipids were both expressed on mast cells derived from fat 
but not on skin mast cells. On the other hand, no proteins were expressed on skin 
mast cells that were not also expressed by fat mast cells. Moreover, this result of 
only two tissue specific mast cell markers suggests that mast cells residing at 
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different connective tissues represent highly similar developmental and functional 
entities. 
3.2.6. Gene ontology analysis of the human mast cell proteome 
Gene ontology enrichment analysis was performed to decipher processes and 
functions specific to human mast cells (Figure 23). 
 
 
Figure 23: Proteome analysis based on human GO analysis for the term 
‘Cellular Component’ 
Shown are Gene-Onthology terms for the category ‘Cellular Component‘ based on 
mast cell enriched proteins depicted as OddsRatio. 
 
In agreement with the mouse mast cell proteome data, proteins belonging to the 
vesicular compartment, and thus falling into vesicle-associated GO:CC terms, were 
presented with the highest OddsRatio values also in human mast cells.  
 
Gene ontology analysis for the term ‘Biological Process‘ (Figure 24) revealed the 
strongest hit for genes categorized to glycosaminoglycan biosynthesis. 
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Figure 24: Proteome analysis based on human GO analysis for the term 
‘Biological Process’ 
Shown are Gene-Ontology terms for the category ‘Biological Process’ based on mast 
cell enriched proteins depicted as OddsRatio. 
 
Overall the human mast cell enriched GO terms in the category ‘Biological process‘ 
display less diversity than the mouse GO:BP. Almost all enriched GO:BP terms in 
human mast cells belonged to ‘Metabolic processes‘.  
 
  
gly
co
sa
mi
no
gly
ca
n c
ata
bo
lic
 pr
oc
es
s
ca
rb
oh
yd
rat
e d
eri
va
tiv
e c
ata
bo
lic
 pr
oc
es
s
ca
rb
ox
yli
c a
cid
 ca
tab
oli
c p
ro
ce
ss
or
ga
nic
 ac
id 
ca
tab
oli
c p
ro
ce
ss
or
ga
no
nit
ro
ge
n c
om
po
un
d c
ata
bo
lic
 pr
oc
es
s
sm
all
 m
ole
cu
le 
ca
tab
oli
c p
ro
ce
ss
lip
id 
bio
sy
nth
eti
c p
ro
ce
ss
ce
llu
lar
 lip
id 
me
tab
oli
c p
ro
ce
ss
ox
ida
tio
n-r
ed
uc
tio
n p
ro
ce
ss
lip
id 
me
tab
oli
c p
ro
ce
ss
or
ga
no
ph
os
ph
ate
 bi
os
yn
the
tic
 pr
oc
es
s
sm
all
 m
ole
cu
le 
me
tab
oli
c p
ro
ce
ss
or
ga
nic
 ac
id 
me
tab
oli
c p
ro
ce
ss
ca
rb
ox
yli
c a
cid
 m
eta
bo
lic
 pr
oc
es
s
ox
oa
cid
 m
eta
bo
lic
 pr
oc
es
s
sin
gle
-or
ga
nis
m 
bio
sy
nth
eti
c p
ro
ce
ss
sin
gle
-or
ga
nis
m 
ca
tab
oli
c p
ro
ce
ss
ion
 tr
an
sp
or
t
sin
gle
-or
ga
nis
m 
pr
oc
es
s
sin
gle
-or
ga
nis
m 
loc
ali
za
tio
n
1
2
4
8
O
dd
sR
at
io
lo
g
GO:Biological Process
Metabolic process
Transport and secretion
Others
Results 
 66 
3.2.7. Human mast cell enriched proteins 
In order to identify novel characteristic and in the best case even unique mast cell 
marker proteins, proteomics data were listed by fold change and their FDR optimized 
p-values (p.adjusted). The list of the top 20 differentially expressed proteins with 
significant fold change in sorted fat mast cells over PBMC is shown in the table 
below.  
 
ProtID	 Symbol	 Protein	name	 log2FC	 pvalue	 padjusted	rep1	 rep2	 rep3	
P23946	 CMA1	 Chymase	 6.452	 2.29E-06	 0.00025	 6.460	 5.704	 7.191	
P15088	 CPA3	 Carboxypeptidase A3	 5.902	 2.54E-07	 0.00025	 5.957	 5.704	 6.047	
Q6NZI2	 PTRF	 Polymerase I and transcript release factor	 5.528	 5.70E-07	 0.00025	 5.255	 5.487	 5.843	
O00534	 VWA5A	 von Willebrand factor A domain-containing protein 5A	 5.269	 3.79E-07	 0.00025	 5.235	 5.203	 5.371	
Q99536	 VAT1	 Synaptic vesicle membrane protein VAT-1 homolog 	 4.964	 8.70E-07	 0.00025	 4.798	 5.261	 4.834	
P08311	 CTSG	 Cathepsin G	 4.898	 1.36E-06	 0.00025	 4.668	 4.734	 5.292	
P21266	 GSTM3	 Glutathione S-transferase Mu 3	 4.847	 1.26E-06	 0.00025	 5.208	 4.645	 4.687	
P51688	 SGSH	 N-sulphoglucosamine sulphohydrolase	 4.772	 2.15E-06	 0.00025	 4.348	 4.807	 5.160	
P27701	 CD82	 Tetraspanin-27	 4.686	 1.63E-06	 0.00025	 4.308	 4.840	 4.910	
Q13237	 PRKG2	 cGMP-dependent protein kinase 2	 4.675	 2.58E-06	 0.00025	 4.802	 5.019	 4.204	
P63096	 GNAI1	 Guanine nucleotide-binding protein G(i) subunit alpha-1	4.626	 2.80E-06	 0.00025	 4.342	 4.418	 5.116	
Q13277	 STX3	 Syntaxin-3	 4.583	 1.49E-06	 0.00025	 4.574	 4.871	 4.306	
P54803	 GALC	 Galactocerebrosidase	 4.400	 2.55E-06	 0.00025	 4.464	 4.717	 4.020	
Q96TA1	 FAM129B	 Niban-like protein 1	 4.389	 1.02E-06	 0.00025	 4.345	 4.492	 4.329	
Q96N66	 MBOAT7	 Lysophospholipid acyltransferase 7	 4.349	 1.87E-06	 0.00025	 4.374	 4.606	 4.069	
P08962	 CD63	 Surface	 4.321	 2.42E-06	 0.00025	 4.660	 4.023	 4.281	
P02545	 LMNA	 Prelamin-A/C	 4.278	 1.25E-06	 0.00025	 4.192	 4.414	 4.227	
P51606	 RENBP	 N-acylglucosamine 2-epimerase	 4.216	 2.07E-06	 0.00025	 4.453	 3.950	 4.245	
Q96AC1	 FERMT2	 Fermitin family homolog 2	 4.115	 1.63E-06	 0.00025	 4.109	 3.974	 4.262	
Table 6: Top 20 proteins enriched in fat mast cells 
Shown are the top 20 protein expression values of fat mast cells compared to PBMC. 
 
As for murine mast cells, we find several mast cell proteases (CPA3, CTSG, CPM 
and CMA1) among the most differential expressed proteins of human fat mast cells. 
Two proteins on top of this list (VWA5A and FAM129B) have not been described in 
mast cells before. In vitro studies suggest that VWA5A may act as a tumour 
suppressor whereas FAM129B has been described as an adherence junction-
associated protein, which was able to suppress apoptosis (Chen et al., 2011). Mast 
cells are long-lived tissue resident cells and one might expect these proteins to 
regulate cell cycle and survival. 
In our previous GO analysis we learned that several metabolic pathways were highly 
enriched in human mast cells. In line with this we find the enzymes MBOAT7 and 
GALC, which are involved in lipid metabolism, and RENBP, which is part of the 
amino-sugar metabolism, within the most enriched proteins in human fat mast cells. 
The enzyme SGSH, which is involved in heparan sulfate degradation, can be clearly 
linked to the core mast cell function of proteoglycan metabolism.  
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Mast cells contain large quantities of intracellular vesicles, thus it is not surprising to 
find proteins involved in endosome formation (PTRF) and synaptic docking (STX3) to 
be highly enriched. We have previously mentioned that mast cells are able to form 
degranulatory synapses. Interestingly, several proteins involved in cell shape and 
polarization were found preferentially expressed in human mast cells. FERMT2 is a 
scaffolding protein required for the assembly of focal adhesions and modulation of 
cell shape, and thus might also play a role in the site directed degranulation of mast 
cells. 
 
With our proteomics screen we aimed to identify novel mast cell specific cell surface 
receptors that might be used as targets in an antibody-based ablation model.  
Therefore, the list of mast cell enriched proteins was filtered for cell surface markers 
as described for the mouse proteome dataset (Table 7). 
 
ProtID	 Symbol	 Protein	name	 log2FC	 pvalue	 padj.	 rep1	 rep2	 rep3	
P27701	 CD82	 Tetraspanin-27	 4.686	 1.63E-06	 0.00025	 4.308	 4.840	 4.910	
P08962	 CD63	 Tetraspanin-30	 4.321	 2.42E-06	 0.00025	 4.660	 4.023	 4.281	
P32004	 CD171	 Neural cell adhesion molecule L1	 4.100	 2.60E-06	 0.00025	 4.363	 4.116	 3.821	
Q9UHX3	 CD312	 Adhesion G protein-coupled receptor E2	 3.655	 2.69E-06	 0.00025	 3.733	 3.644	 3.588	
Q9P121	 NTM	 Neurotrimin	 4.052	 3.16E-06	 0.00027	 3.711	 4.286	 4.157	
Q96LB1	 MRGPRX2	 Mas-related G-protein coupled receptor X2	 3.816	 3.65E-06	 0.00029	 3.730	 3.611	 4.108	
P05026	 ATP1B1	 Sodium/potassium-transporting ATPase beta-1	 3.627	 5.03E-06	 0.00030	 3.803	 3.314	 3.763	
P10721	 CD117	 Mast/stem cell growth factor receptor Kit	 4.543	 6.91E-06	 0.00033	 3.999	 4.468	 5.161	
Q96QE2	 SLC2A13	 Proton myo-inositol cotransporter	 3.030	 1.34E-05	 0.00042	 3.208	 2.715	 3.167	
O43699	 SIGLEC6	 Sialic acid-binding Ig-like lectin 6	 4.673	 1.41E-05	 0.00043	 3.813	 5.252	 4.955	
P11279	 CD107a	 Lysosome-associated membrane glycoprotein 1	 2.673	 2.21E-05	 0.00054	 2.414	 2.747	 2.859	
O14638	 CD203c	 Nucleotide pyrophosphatase 3	 3.081	 2.65E-05	 0.00059	 2.609	 3.156	 3.479	
Q96GQ5	 C16orf58	 RUS1 family protein C16orf58	 2.683	 2.75E-05	 0.00060	 2.458	 2.579	 3.011	
Q8WWI5	 CD92	 Choline transporter-like protein 1	 2.653	 2.77E-05	 0.00060	 2.786	 2.839	 2.333	
P08582	 CD228	 Melanotransferrin	 2.676	 2.81E-05	 0.00061	 2.723	 2.362	 2.942	
Q9Y5S1	 TRPV2	 Transient receptor potential cation channel V2	 2.629	 3.46E-05	 0.00068	 2.356	 2.979	 2.553	
P19634	 SLC9A1	 Sodium/hydrogen exchanger 1	 3.230	 3.82E-05	 0.00072	 2.583	 3.509	 3.598	
Q9NYZ4	 SIGLEC8	 Sialic acid-binding Ig-like lectin 8	 3.233	 4.03E-05	 0.00073	 2.855	 3.894	 2.952	
P16070	 CD44	 Hyaluronate receptor	 3.246	 4.23E-05	 0.00075	 2.618	 3.782	 3.339	
Table 7: Top 20 cell surface proteins enriched in fat mast cells 
Shown are the cell surface protein expression values of sorted fat mast cells / PBMC 
PEC. Only proteins with a p.adjusted > 0.01 are listed. 
 
In addition to the prototypic mast cell marker CD117, the top 20 mast cell enriched 
cell surface proteins contained several novel mast cell specific markers that could be 
functionally divided into distinct groups. Adhesion molecules, among which were 
CD171, CD312, NTM, SIGLEC6, SIGLEC8 and CD44, constituted the largest group. 
These molecules, might act in concert to mediate migration of mast cell precursors 
from the bone marrow into the periphery and regulate the maintenance of mast cells 
in their tissue niche. CD171 has recently been described as a marker for human skin 
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mast cells (Gschwandtner et al., 2017). Our proteomics screen found CD171 to be 
also specifically expressed on fat mast cells, suggesting that skin and fat mast cells 
have a similar phenotype. CD312 is a receptor for chondroitin sulfate and mediates 
adhesion to it (Stacey et al., 2003). It has been shown that in neutrophils CD312 
ligation results in adhesion and migration, and augments superoxide production and 
degranulation (Yona et al., 2008). As neutrophils and mast cells have overlapping 
functions, CD312 might enhance mast cell degranulation and adhesion. Channel 
proteins were the second largest group represented on our list of mast cell specific 
surface proteins: ATP1B1, SLC2A13, CD92 and SLC9A1 transport ions and small 
metabolites across the plasma membrane. 
The third group of receptors is involved in the transmission of signals from the 
environment across the plasma membrane. Analogous to mouse mast cells we found 
tetraspanins to be highly expressed in human mast cells. CD82 and CD63 are the 
most enriched proteins detected in mast cells and their mast cell specificity appears 
to be conserved across species. A high degree of homology between mouse and 
human (76,4% for CD82; 79.4% for CD63) suggests similar function, however wether 
they are truely functionally homologous remains to be determined. CD203c is 
involved in the hydrolysis of extracellular oligonucleotides, nucleoside phosphates, 
and NAD and thus contributes extracellular nucleotide signalling. MRGPRX2 is a G-
protein coupled receptor that mediates mast cell degranulation by non-immunologic 
secretagogues, such as compound 48/80, and is able to bind cathlicidin (McNeil et 
al., 2015; Subramanian et al., 2016). TRPV2 is an ion channel that is activated by 
temperatures above 52°C. TRPV2 activation results in Ca2+ influx and degranulation 
(Zhang et al., 2012). The closest ortholog of C1orf58 has been described in the root 
of Arabidopsis thaliana and mediates the sensing of low energetic ultra-violet light 
during root development (Tong et al., 2008). Mast cell activation in response to UV-
irradiation has been described in certain settings, however the precise mechanism of 
such cellular activation has not been elucidated (Hart et al., 2000).  
 
3.2.8. Verification of novel human mast cell markers 
Having identified a variety of differentially expressed cell surface proteins in the 
proteomics dataset of human fat and skin mast cells, we next analyzed their specific 
surface expression by antibody staining. In addition to fat and skin, we isolated lung 
and colon mast cells, and tested these for mast cell marker expression. For several 
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of the listed proteins (Table 7) monoclonal antibodies are commercially available. We 
tested by flow cytometry the expression of CD171, CD82, CD312, CD63, MRGPRX2 
CD117, SIGLEC6, CD107a, CD203c and CD92 on the different cell populations 
listed below. Human fat, lung, colon and skin mast cells (CD14- CD45+ CD117+ IgE+), 
as well as peripheral blood monocytes (CD45+ CD14+), basophils (CD45+ CD123+ 
FcεRI+), eosinophils (CD45+ SSChi CD193+), neutrophils (CD45+ CD16+), 
plasmacytoid dendritic cells (CD45+ CD123+ FcεRI+-), B cells (CD45+ CD3- CD19+), 
CD4 T cells (CD45+ CD3+ CD4+), and CD8 T cells (CD45+ CD3+ CD4-) were stained 
with these monoclonal antibodies, or isotype controls (Gating strategy in Supplement 
Figure 3).  
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Figure 25: Flow cytometry of the 10 most enriched human mast cell surface 
proteins 
a) Example for the tested antigens, histogram overlays are shown for SIGLEC6 
antibody staining (red) and isotype control (black) on human fat, lung, colon and skin 
mast cells as well as peripheral blood monocytes, basophils, eosinophils, neutrophils, 
dendritic cells, B cells, CD4 T cells, and CD8 T cells.  
b,c) The same 12 Populations depicted in (a) were tested for immunoreactivity 
against the antigens CD171, CD82, CD312, CD63, MRGPRX2 (b) or CD117, 
SIGLEC6, CD107a, CD203c and CD92 (c) by flow cytometry. Shown is the mean 
staining index ± SEM of 1-6 samples per group. 
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All ten markers that were analysed by flow cytometry were found to be expressed on 
fat and skin mast cells, thereby confirming the results obtained from the mass 
spectrometry-based screening. 
Interestingly, human lung and colon mast cells did not stain positive for MRGPRX2, 
which previously has been described to be predominantly expressed by the 
connective tissue type mast cells (MCTC) but not by mucosal MCT (Subramanian et 
al., 2016). CD171 might also be preferentially expressed on MCTC as it was 
undetectable on lung mast cells and staining with anti-CD171 antibody revealed two 
populations of colon mast cells. In the colon, mucosal MCT as well as connective 
tissue MCTC are present, thus it is possible that CD171 discriminates between the two 
mast cell subtypes in the gut.  
With respect to specificity, MRGPRX2, CD117, SIGLEC6 and CD203c were 
exclusively found on mast cells but not on other blood cell lineages. CD82 and CD92 
were detected on both, mast cells and blood leukocytes, albeit with approximately 10 
fold higher levels on mast cells.  
The protein CD312 was found with similar staining intensities on mast cells from all 
analysed tissues and on the myeloid subsets as well as on plasmacytoid dendritic 
cells, but not on lymphocytes. This is in line with a previous report suggesting a role 
for CD312 in migration and adhesion of cells from the myeloid lineage (Chang et al., 
2007a).  CD63 and CD107a staining could be detected on all cell types, except CD4 
T cells and pDCs. This expression pattern of human CD63 is therefore somewhat 
unexpected, as the homologous mouse protein showed extraordinary mast cell 
specificity. However, all mast cell subsets exhibit a 2-10 fold stronger staining 
intensity of CD63 and CD107a over other hematopoietic cells tested.  
In addition to the top 5 enriched proteins this experiment was also performed for the 
markers: SIGLEC8, FcεRI, CD26, CD44, CD51, CD59 and CD54 (Supplement figure 
4), all of which are mast cell enriched proteins . 
3.2.9. Mapping of skin MC RNA-sequencing data to skin MC 
proteome 
There has been a recent human transcriptome analysis by the FANTOM consortium 
for the identification of mast cell specific genes (Motakis et al., 2014). By comparing 
RNA expression of purified human skin mast cells to transcriptome data from a 
collection of 893 FANTOM5 samples, including various immune cells from peripheral 
blood, a list of 169 genes was generated (Supplement Motakis et al., 2014) which 
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were enriched by at least 10-fold in skin mast cells compared to the mean of all 
FANTOM5 samples. 
To compare the mast cell specific genes identified from the FANTOM5 samples we 
mapped them onto our skin mast cell versus PBMC proteomic data (Figure 26). From 
the 169 genes we were able to map 51. The other 118 genes were not detected by 
the mass spectrometer, which might be a result of under sampling, but might also 
indicate that the protein expression level of such proteins is low in primary human 
mast cells. In addition, 30 genes that displayed strong mast cell-specificity in the 
FANTOM screen mapped to proteins that were not signifcantly upregulated in our 
proteome data. This discrepancy between RNA abundance and protein abundance 
might reflect gene regulatory differences on transcriptional and post-translational 
level. It has been estimated that mRNA levels only explain 40% of the variability 
observed on protein levels, and that protein abundance is predominantly regulated at 
the ribosome by means of translational control (Schwanhausser et al., 2011). 
 
 
Figure 26: Comparison of RNA-sequencing to proteomics 
Shown is the protein expression of sorted skin mast cells relative to PBMC versus 
the p.adjusted values. Proteins without significant change in expression are 
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displayed in grey. Proteins with 2-fold expression change are either coloured in red 
(higher expressed) or blue (lower expressed). Mast cell enriched genes identified by 
Motakis et al. are indicated with names and arrows. 
 
As we were mainly interested in identifying mast cell enriched surface receptors we 
also compared the two data sets with focus on cell surface proteins. Of the 20 most 
enriched cell surface proteins, identified with our proteomics screen we only found 
CD82, SIGLEC8 and P2RX1 enriched on RNA as well as on protein level. This 
observation is not surprising as particularly for cell surface proteins the correlation of 
RNA and protein expression has been reported to be weak (Cox et al., 2009; 
Lundberg et al., 2010).  
Therefore proteomic profiling is superior to RNA analysis in identifying novel mast 
cell enriched cell surface receptors. 
3.2.10. Human – mouse mast cell comparison 
The previous GO term analysis revealed an enrichment of comparable biochemical 
pathways in mouse and human mast cells. Such similarities suggest conserved 
functions of mast cells in mice and humans. To understand the molecular basis for 
these conserved functions, we performed an in-depth comparison of proteins 
enriched in mouse peritoneal mast cells (peritoneal mast cells / Cpa3Cre/+ PEC) and 
proteins enriched in human fat mast cells (fat mast cells / PBMC). Quantified proteins 
from the mouse and human datasets were compared, and based on their Ensembl 
annotation 378 proteins could be assigned to their homologs (Ensembl does not 
“know” all homologs). From these, 33 proteins were more expressed in mouse and 
human (Figure 27b), 4 were more expressed in mouse mast cells (Figure 27c), and 3 
were more expressed in human mast cells (Figure 27d).  
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Figure 27: Cross-species conserved mast cell protein signature 
a) Expression of mouse mast cell enriched proteins (vertical axis) versus human fat 
mast cell enriched proteins (horizontal axis) shown in log scale. Proteins significantly 
different in both mouse (ms) and humans (hu) are coloured in red; proteins 
significantly changed in mouse only are coloured turquoise and proteins significantly 
changed in human only are depicted as blue. b) The table shows the proteins that 
are specifically enriched in mast cells of both species (p=0.01). c-d) the tables show 
proteins solely enriched in mouse and humans respectively (p=0.01). Typical mast 
cell markers are marked by arrows and indicated with their names. 
 
 
Based on this analysis we could identify a proteome signature for mast cells, which 
contains 33 proteins that were homologous between mouse and humans and were 
specifically and strongly expressed (upper right red dots and red box in Figure 27a 
and b, respectively). There are more blue dots visible as in the human dataset more 
proteins could be quantified in the Fat MC / PBMC comparison. The conserved 
genes can be grouped into six categories: proteases and protease inhibitors (CPA3, 
CTSG, LXN); bioactive amine metabolism (SLC18A2, MAOB); proteoglycan 
metabolism (NAGLU, SGSH, GNS, HEXB); granule machinery and cellular plasticity 
proteins (VAT1, BASP1, STXBP2, UNC13D, SYTL3, STX3); receptors for binding 
and responding to environment (FAM129b, CD117, P2RX1, CD63, CD82); and 
others (VWA5A, RAB27B, MYO1D, RAB44, SDSL, EPDR, OSBPL8, EML2, ARSA, 
NAGA, TNS1, HSPA2, GGH). 
By comparing the mouse and human mast cell enriched proteins we detect core mast 
cell functions that are conserved across species suggesting that mast cells in both 
species are similar in function.  
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3.3. In vivo depletion of mast cells via targeting of the 
endogenous marker CD63 
Next, we sought to investigate if the identified surface markers on mast cells would 
be suitable for antibody-mediated depletion. One of the most enriched mouse and 
human mast cell receptors identified is the tetraspanin CD63 (Figure 19b). CD63 is 
expressed not only in mast cells but also in granulated cells such as basophils, 
cytotoxic T cells, platelets and certain subsets of endothelial cells. However, due to a 
lysosomal targeting sequence, CD63 is thought to be retained within lysosomes, and 
only becomes exposed on the cell surface under conditions of granule exocytosis. 
This hypothesis is also supported by our flow cytometry data, which show specific 
cell surface staining of murine CD63 among the hematopoietic cell types tested. In 
addition, human and mouse mast cells of various origin have reportedly shown 
consistent cell surface expression of CD63 (Köberle et al., 2012). 
Based on these considerations, CD63 may be a suitable target for antibody-mediated 
mast cell depletion. 
3.3.1. ADCC-dependent depletion mechanism 
According to the ADCC-dependent depletion of mast cells from huCD4-transgenic 
mice with TNX355 (anti-huCD4) antibodies, we tested the in-vivo mast cell depletion 
ability of the anti-CD63 antibody NVG-2 (rIgG2b). Therefore, C57BL/6 Cpa3hCD4/hCD4 
mice were injected once i.p. with 500µg NVG-2. Control mice were treated with 
A161A1 (anti-hCD4, rIgG2b), TNX355 (anti-hCD4, msIgGa), or the respective isotype 
control antibodies (Figure 28). On day 7 after injection, mice were sacrificed and 
peritoneal mast cell depletion was measured by flow cytometry. 
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Figure 28: Anti-CD63 mediated mast cell ablation 
C57BL/6 Cpa3hCD4/hCD4 mice were treated i.p. with 500µg of anti-CD63, anti-hCD4, 
TNX355 or isotype control antibodies in 200µl of PBS. 7 days later mice were 
sacrificed and peritoneal exudate was isolated for subsequent flow cytometric 
evaluation of mast cell ablation. a) Representative FACS plots of the different 
peritoneal exudate cells. Numbers indicate percentages of mast cells within the live, 
F4/80-, CD45+ gate. b) The number of phenotypic mast cells per 105 CD45+ cells is 
shown. Mean ± SEM for two animals per treatment group. 
 
A single intra-peritoneal injection of 500µg of anti-CD63 antibody did not result in any 
reduction of peritoneal mast cells (Figure 28). Treatment of mice with equal amounts 
of anti-hCD4 antibody (A161A1 or TNX355) resulted in near complete peritoneal 
mast cell depletion. Isotype control antibodies had no effect on mast cell numbers. 
Therefore, CD63 does not seem to be an effective target for ADCC-mediated mast 
cell depletion. This could be due to the fact that CD63 is more rapidly internalized 
upon antibody binding than the artificial hCD4 molecule and thus, in contrast to anti-
hCD4 antibodies, NVG-2 may not efficiently activate a cellular cytotoxicity response. 
3.3.2. Fluorimetric measurement of anti-CD63 internalization 
To test whether bound antibody internalizes after binding with CD63, we coupled the 
pH sensitive reporter pHrodo to the anti-hCD63 antibody (C5H6). PHrodo is a 
fluorescent dye with excitation and emission maxima at 560 nm and 585 nm, 
respectively. Its fluorescent emission intensity is enhanced by orders of magnitude at 
acidic pH. We incubated primary human skin and fat mast cells on ice or at 37°C in 
the presence of anti-CD63-pHrodo or Isotype-pHrodo antibodies. Internalization into 
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acidic endosomal compartments was observed by measuring the increase of mean 
fluorescence intensity by flow cytometry at 37°C (Figure 29). 
 
 
Figure 29: Anti-CD63 is internalized into primary human skin mast cells 
Shown is the increase in mean fluorescence intensities of cultured human skin mast 
cells after incubation with anti-CD63-pHrodo or isotype-pHrodo antibodies at 37°C at 
the indicated time points.  
 
Antibody binding to CD63 induced internalization in human skin mast cells. 
Internalization of bound antibody follows very rapid kinetics as fluorescent pHrodo 
can be detected as early as 1 minute after addition of the antibody to the culture 
medium. 
These experiments with human mast cells suggest that CD63 is rapidly internalized 
and thus might not be available on the cell surface for effector cell binding. 
Alternative strategies for CD63-mediated cell depletion therefore are required, e.g. 
application of antibody-drug conjugates. 
 
3.3.3. CD63 targeting by antibody-drug-conjugate 
Antibody-drug conjugates (ADCs) usually follow a three-step mechanism of action. 
First the antibody, attached to the payload, binds its target on the cell surface. 
Secondly, the receptor-antibody complex is internalized. Next, within the endosome 
the cytotoxic drug is released from the antibody by endogenous peptidase cleavage. 
In a last step the toxin is transported to the cytosol where it interferes with essential 
cellular processes resulting in apoptotic cell death of the target cell. 
 
0 24 48
0
500
1000
1500
2000
2500
time (h)
M
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
Isotype-pHrodo
hCD63-pHrodo
Results 
 78 
Having shown that CD63 is rapidly internalized after antibody binding, we were 
interested whether it might be a suitable target for antibody-drug-conjugate-mediated 
mast cell ablation. The drug conjugate we chose was saporin. This is a ricin derivate 
that is able to enzymatically inactivate ribosomes resulting in a shut down of protein 
synthesis, eventually leading to apoptosis. saporin is commercially available as an 
attachment to streptavidin and can therefore tightly be bound to biotinylated 
antibodies of interest. 
 
To test whether a CD63-saporin conjugate may efficiently kill mast cells, we prepared 
an equimolar mixture of biotinyliated anti-CD63 (clone NVG-2) and streptavidin-
saporin (SAP) and incubated murine bone marrow-derived mast cells and mouse 
primary peritoneal mast cells with different amounts of that ADC-complex. Cell death 
was determined by measuring the decrease of viable cells, 72 hours after treatment, 
using the fluorescent redox viability assay CellTiter-blue (Promega) (Figure 30).  
 
 
 
Figure 30: In vitro mast cell killing with CD63-saporin 
C57BL/6 bone marrow-derived mast cells (BMMC) and peritoneal-exudate derived 
mast cells (PMC) were treated with different concentrations of CD63-saporin. After 
72 hours the amount of viable cells was determined by CellTiter-Blue viability assay. 
 
Internalization of CD63-saporin resulted in the specific cell death of both BMMC and 
PMC. Incubation of cells with a control mixture, (in which the Toxin is not specifically 
bound by the antibody) consisting of phycoerythrin-conjugated antibody (CD63-PE) 
and SA-Saporin, did not induce cell death. This experiment demonstrated that mast 
cells could specifically be killed with CD63-saporin, in vitro. 
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Next, I investigated the in-vivo mast cell ablation capability of CD63-SAP. C57BL/6 
wild type mice were injected i.v. with 100 µg CD63-SAP or the corresponding amount 
of 40 ug SAP only. Animals were monitored daily for the occurrence of toxicities. 
Seven days after treatment, mice were sacrificed and mast cell depletion was 
quantified by flow cytometry. 
 
 
Figure 31: In vivo depletion of wild type mast cells with a CD63-saporin 
conjugate  
C57BL/6 mice were treated i.v. with 100µg of CD63-SAP or naked SAP in 200µl of 
PBS. 7 days later mice were sacrificed and organs were isolated for subsequent flow 
cytometric evaluation of mast cell ablation. a) The absolute number of phenotypic 
mast in different organs is shown. Mean ± SEM for three animals per treatment 
group. b) Representative FACS plots of the different mast cell compartments. 
Numbers indicate percentages of mast cells within the live, CD3-, CD19-, CD11bint, 
CD45+ gate. 
 
CD63-SAP did not exhibit anti-mast cell activity in vivo. From day 5 after treatment, 
two of the mice that received CD63-SAP displayed weight loss, hunch back, and 
impaired mobility. Upon necropsy, a shrunken stomach and vastly reduced 
epididymal fat could be observed in the CD63-SAP treated animals. Due to the 
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deterioration, it was not possible to perform flow cytometry on single cell suspensions 
from fat and stomach tissue. However, due to lack of mast cell ablation efficacy we 
did not further investigate the cause of the observed toxicities. 
 
These results suggest that CD63 might not be a suitable target for in vivo ADCC- and 
ADC-mediated mast cell ablation due to its toxicity, possibly in the kidneys. 
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4. Discussion 
Current therapeutics only target mast cells indirectly by neutralsation of secreted 
mediators or by reducing the activation capacity.  In some patients symptomatic 
treatment strategies are often insufficient to control the very severe allergic diseases. 
In these instances, novel therapeutic agents are required, as affected patients 
depend on frequent, high dosed drugs to control their disease while sustaining a 
particular high risk of morbidity and mortality (Holgate and Polosa, 2008; Pakhale et 
al., 2011; Serra-Batlles et al., 1998). Monoclonal antibody therapy is successfully 
pursued in all current areas of drug development. Here, we present an experimental 
approach aimed at specifically eliminating mast cells by cell-depleting monoclonal 
antibodies. 
4.1. Mouse mast cell proteomics 
To identify physiologic mast cell antigens we established a mass-spectrometry 
assisted proteomics pipeline for primary mast cells. While, previous efforts of large-
scale analysis of mast cells mostly focussed on the mast cell mRNA expression, we 
sought to analyse protein expression. RNA-based assays (microarray or RNA-
sequencing) are useful to detect cell-type specific transcripts, however, protein 
abundance can be regulated at the ribosome. For cell surface proteins in particular 
the correlation of RNA presence and protein abundance may be poor (Cox et al., 
2009; Lundberg et al., 2010). Moreover, many of the previously published 
transcriptome datasets relied on in vitro differentiated immature mast cells or 
immortalized mast cell lines (Jayapal et al., 2006; Nakajima et al., 2002; Sayama et 
al., 2002). In vivo, MCs develop from progenitors in the bone marrow and migrate as 
immature cells into the periphery (e.g. skin, lung, gut) where they complete their 
maturation (Gurish and Austen, 2012). Therefore, it is unclear to what extent mast 
cells generated by in vitro differentiation represent their mature tissue counterparts in 
vivo. In support of this note of caution, a recent report demonstrated that primary 
MCs undergo profound changes when placed into a cell culture environment 
(Motakis et al., 2014). 
To decipher the proteome of mature tissue mast cells we isolated primary mast cells 
by FACS-sorting from the peritoneal cavity of C57BL/6 mice. Mast cells from the 
Discussion 
 82 
peritoneal cavity are easily purified and minimize bias introduced by enzymatic tissue 
digestion. There are two main strategies for investigating the proteome of membrane 
proteins. Traditionally, density gradient separation was used to separate the 
membrane fraction from the organelle and nuclear proteins. In more recent years, 
biotin or lectin labelling approaches have been successfully developed to tag and 
capture cell surface proteins (Elschenbroich et al., 2010). The large quantities of 
cellular proteins required for such direct membrane fraction isolation procedures 
were impossible for primary mast cells in our hands. We therefore first determined 
the whole mast cell proteome without fraction pre-enrichment, and subsequently 
selected surface expressed proteins from this entire data set by bioinformatic criteria. 
For the quantification of proteins in a mass-spectrometry experiment it is required to, 
include an internal standard, or to measure differentially labelled protein samples 
side-by-side. For explorative mass spectrometry it is not possible to include a 
standard, as the composition of proteins in the experiment is unknown. For these 
experiments side-by-side comparisons are useful, which can be achieved in different 
ways. Typically the digested peptides are differentially labelled with stable isotopes. 
The basis for this strategy is the stable isotope dilution theory, which in principle 
states that a stable isotope-labelled peptide has the same physiochemical properties 
as its unlabelled counterpart, and thus will behave the same way during 
chromatographic separation and mass acquisition. The mass spectrometer can 
recognize these differentially labelled peptides and quantify them based on signal 
intensities (Bantscheff et al., 2007). In our experiments we used stable dimethyl 
labelling of trypsin-cleaved peptides (Boersema et al., 2009). 
Previous studies from our laboratory analysed mRNA expression of skin whole tissue 
lysates (Feyerabend et al., 2011). In this study whole skin mRNA expression from 
mast cell-deficient Cpa3Cre/+ and mast cell-sufficient Cpa3+/+ mice were compared, 
and mast cell specific genes could be identified as differentially expressed mRNA 
without prior purification of mast cells. 
Based on these findings, we reasoned that mast cell-specific proteins might easily be 
identified when comparing peritoneal cells of Cpa3Cre/+ and Cpa3+/+ mice. However, in 
contrast to the RNA-microarray of skin tissue, the proteomic comparison of Cpa3+/+ to 
Cpa3Cre/+ PEC displayed only minimal difference in detection of mast cell-specific 
markers. Unlike RNA-based screenings, the coverage of mass spectrometry-assisted 
proteomics experiments is estimated to be less than 10% of the genome, which 
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makes it difficult to detect rare proteins. Mast cells make up only 2-4% of all 
peritoneal cavity cells. Thus, the Cpa3+/+ and Cpa3Cre/+ PEC samples are too similar 
and the mast cell-specific proteins are too rare compared to all the proteins in the 
sample in order to be readily detected by the mass spectrometer.  
To overcome this limitation (Bantscheff et al., 2007) we compared sorted mast cells 
vs. total peritoneal cells. This revealed abundant MC-specific proteins, as the mass 
spectrometer can detect sufficient proteins from the sorted mast cell sample. As 
expected, the MC / Cpa3Cre/+ comparison was more sensitive in detecting mast cell-
specific proteins as there were more proteins significantly up- or down regulated in 
the MC vs. Cpa3Cre/+ dataset (n=144) than in the MC vs. Cpa3+/+ dataset (n=122)).  
We found several proteases (Cpa3, Cma1, Tpsb2 and Ctsg) among the proteins that 
displayed the highest fold change comparing the proteomes of mast cells and the 
remaining peritoneal cells. Hence, proteases may be regarded as bona fide mast cell 
protein markers. Some of the mast cell enriched proteins are also abundantly 
expressed in brain tissue. Among these are: Basp1, Slc29a1, CD56, Slc6a4 and 
Slc16a1 that play roles in synapse formation and neurotransmitter release. Mast cells 
are well known for their role in histamine and serotonin release, which also have 
important function as neurotransmitters in the brain (Theoharides et al., 1982). We 
were also able to confirm this function of mouse mast cell proteins by gene set 
enrichment analysis, as the two most prominently enriched features in the GO 
category ‘Biological process’, are serotonin transport and glucosamine metabolism. 
With regard to synapse formation, it has only recently been shown that mast cells 
can form directional degranulatory synapses towards IgE coated cells and parasites 
in vitro (Joulia et al., 2015). 
Among the top 20 candidate cell surface markers we find three groups of proteins 
that may be useful target proteins for cell ablation. The first group consists of 
receptors such as Il-1rl1, CD117 and FcεRI, which are well-known mouse mast cell 
specific markers. Cell surface proteins such as CD63, CD81, CD82, CD43, CD34, 
Slc7a8 and P2rx7 form the second group, which appear in several published high-
throughput RNA or antibody binding screenings, but for which mast cell specificity 
has not been interrogated (Agis et al., 1996; Dwyer et al., 2016; Köberle et al., 2012; 
Saito, 2005; Valent et al., 2014). And lastly, a group of proteins such as Slc6a1, 
Slc16a1, P2rx1, Ada and CD56 that are not well known as mast cell specific proteins. 
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While the mouse mast cell markers presented here are not novel in each case, this is 
the first report of a quantitative mass spectrometry-assisted assessment of mast cell-
specific protein expression, and subsequent validation by flow cytometry. Thus, our 
data shall allow unprecedented conclusions about mouse mast cell-specific protein 
expression. 
4.2. Human mast cell proteomics 
The proteomics pipeline for detecting mast cell specific markers was established with 
murine mast cells. For human cells however, acquisition of sufficient amount of mast 
cells for mass spectrometry was a challenge. We decided to isolate primary mast 
cells from skin and fat tissue from patients undergoing voluntary cosmetic surgery. 
To overcome individual patient-derived variability of isolated human mast cells we 
chose to pool preparations of purified mast cells from three patients for each 
analysis. Purified skin mast cells, purified fat mast cells, and peripheral blood 
mononuclear cells (PBMCs) were differentially labeled and analysed. Technically, the 
experiment with human mast cells was very similar to the mouse mast cell 
proteomics. The measured peptide counts and numbers of identified proteins were in 
a similar range. However, in contrast to the data from mouse mast cells, the direct 
comparisons of human mast cells to non-mast cells (PMBCs) revealed considerably 
more differentially regulated proteins. The PBMC sample contains more diverse cell 
types than the peritoneal cells used for the mouse proteomics experiment the results 
most likely reflect a higher complexity proteins within PBMC. Skin and fat mast cells 
have very similar proteomes, as both belong to connective-tissue type mast cells 
(MCTC). However, the MCTC compartments in different tissues may be regulated or 
influenced by local microenvironmental factors (Moon et al., 2009). Indeed, we 
detected 5 proteins that were differentially expressed between fat and skin mast 
cells, suggestive of tissue-specific differences. 
In line with the findings obtained from mouse mast cells, human mast cells 
specifically express characteristic proteases (CPA3, CTSG, CPM and CMA1). Apart 
from the proteases, the metabolic enzymes SGSH, GALC, RENBP and MBOAT7, as 
well as several other proteins, such as VWA5A and FAM129B with unknown 
function, were highly enriched in human mast cells. GO analysis revealed enrichment 
of glucosamine metabolism which is in agreement with well known functions of mast 
cells in heparin and chondroitin sulphate synthesis (Rönnberg et al., 2012).  
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Human mast cell specific antigens that we identified by our comparative proteomic 
screen may be divided into three main groups. The first group of proteins consists of 
receptors such as MRGPRX2, CD117, and FcεRI, which are well-known human mast 
cell specific markers. (Gurish et al., 1992; Kraft, 2005; McNeil et al., 2015). Cell 
surface proteins such as CD63, CD82, CD171, CD312, SIGLEC6, SIGLEC8, 
CD107a, CD203c, TRPV2, and CD44 form the second group, which appear in 
several published high-throughput RNA or antibody binding screenings, but for which 
mast cell specificity has not been interrogated (Florian et al., 2006; Ghannadan et al., 
1998; Motakis et al., 2014; Valent et al., 2014), and for which a function in mast cells 
has been either shown or might be inferred from experiments with other cell types. 
The third group of proteins consists of NTM, ATP1B1, SLC2A13, C1ORF58, CD228, 
SLC9A1, and others, which are poorly recognised as mast cell specific proteins. 
Interestingly, we also found molecules related to the neuronal system enriched in 
human mast cells. Among these are CD171 (L1 neural cell adhesion molecule), NTM 
(Neurotrimin) and CADM1 (Cell adhesion molecule 1). Whether mast cells use these 
molecules to establish interactions with nerve cells is currently under debate (van 
Diest et al., 2012). 
 
In general, human mast cells are characterised by the protease content of their 
granules into MCT and MCTC (Galli et al., 2011; Gurish and Austen, 2012). In addition 
to protease content, differential cell surface antigen expression has been postulated. 
The G-protein coupled receptor MRGPRX2, for example, was found to be selectively 
expressed on MCTC but not MCT (Subramanian et al., 2016). Our flow cytometry data 
confirmed the MCTC specific expression of MRGPRX2 on skin and fat mast cells, 
while lung or intestinal mast cells did not stain for MRGPRX2. In addition, our data 
indicate that CD171 might be discriminative for MCT from MCTC as well. Skin and fat 
mast cells, which are thought to be exclusively MCTC, stained uniformly for CD171, 
while alveolar mast cells, considered almost entirely of MCT-type, stained negative 
for CD171. Mast cells staining positive or negative could be found in intestinal tissue, 
which is known to contain both subtypes of mast cells (Irani et al., 1986; Schwartz et 
al., 1987).,  
 
Given that RNA abundance may be a poor indicator of protein abundance (Cox et al., 
2009; Lundberg et al., 2010), we were interested to compare the recently published 
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RNA-sequencing dataset of human skin mast cells with our proteomics data of 
human skin mast cells (Motakis et al., 2014). The FANTOM5 consortium generated 
RNA-sequencing datasets of more than 893 different human tissues and cell types. 
Motakis and colleagues generated a list of mast cell specific transcripts by comparing 
the RNA expression of purified skin mast cells to the 893 FANTOM5 samples. This 
list contains 169 genes that were at least 10-fold enriched on RNA level. However, 
when we probed these 169 genes to our skin mast cell proteome data set, only 30 of 
the 169 mast cell specific transcripts were significantly enriched on protein level. This 
result is particularly interesting as the FANTOM5 consortium included all major 
hematopoietic cell types in their search for mast cell specific transcripts, which is 
similar to the PBMC comparison we used. We conclude that there is poor overlap of 
RNA and proteome data in human mast cells. Thus, we conclude that mass 
spectrometry-based target discovery may be superior to RNA-based searches. 
4.3. Evolutionary conserved mast cell proteome 
By comparing the specifically enriched proteins of mouse peritoneal mast cells and 
human fat mast cells, we identified a common mast cell signature of 33 orthologous 
proteins. The similarity of mouse and human mast cell enriched proteins suggests a 
mast cell core functionality that has been evolutionary maintained. In depth analysis 
of the cross-species conserved proteins by grouping them into functional pathways 
revealed 5 clusters: proteases and protease-inhibitors, histamine/serotonin 
metabolism, proteoglycan metabolism, granule exocytosis machinery, and cell 
surface receptors for responding to environmental cues. All of these functions are 
already present in the so-called “test-cells”, from the urochordates, dating back over 
500 million years ago (Cavalcante et al., 2002; de Barros et al., 2007). These ancient 
highly granulated cells have been found to associate with the ascidians’ oocytes. 
Upon stimulation, e.g. with compound 48/80, test cells release tryptase and have 
been postulated to be part of a rudimentary immune system, providing the oocyte 
protection against microbial infections (Cavalcante et al., 2002; Ribatti and Crivellato, 
2014). In our proteomics screen we found the orthologous protein pair 
Mrgprb2/MRGPRX2 enriched in mouse and human mast cells. In 2011 it was shown 
that MRGRX2 (MRGPRX2), expressed on cultured human mast cells, may be 
activated by compund 48/80 (Kashem et al., 2011).  
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Altogether our data support the view that mast cell degranulation and the release of 
histamine, heparin and proteases have been conserved over 500 million years. While 
FcεRI was acquired in parallel to the appearance of IgE antibodies in mammals 
about 200 million years ago the mast cell proteases diversified and acquired different 
specializations, ranging from degradation of venoms to possibly, regulation of 
endogenous homeostasis (Pejler et al., 2007; Ribatti and Crivellato, 2014). 
The evolutionary maintenance of mast cells, suggests important function. However, 
the most prominent function of mast cells, i.e. IgE-mediated immediate 
hypersensitivity reactions appears to mostly contribute to pathology. These functions 
of mast cells decrease the fitness of the host and hence would be negatively selected 
during evolution. This discrepancy suggests so far unknown beneficial mast cell 
functions, which may lie outside the classical field of immunology and allergy (Palm 
et al., 2012). 
4.4. Anti-hCD4-mediated mast cell ablation 
Successful cellular targeting by monoclonal antibodies depends on several factors. 
First, the molecule that is targeted needs to be accessible for antibodies, and thus to 
be exposed on the cell surface. Secondly, the expression of the molecule has to be 
mast cell specific in order to minimize side effects. The third requirement depends on 
the selected cell ablation mechanism. In the case of antibody dependent cellular 
cytotoxicity (ADCC), the targeted receptor should not be internalized, while for 
antibody-drug conjugates (ADC) the internalization of the targeted receptor is a 
prerequisite to deliver the toxin into the cell, its site of action. In ADCC, FcγR-bearing 
immune cells induce killing of the target cell, thus the antibody isotype is critical for 
effector cell binding, as well. For ADC, Fc-functions of the antibody are rather 
undesired as immune cell binding via FcγR may foster off target effects (Scott et al., 
2012).  
 
In order to explore antibody-mediated mast cell targeting we made use of the 
previously developed Cpa3hCD4 mouse model (Feyerabend et. al., unpublished). In 
this model, a chimeric hCD4 molecule, consisting of two Ig domains of human CD4 
and the transmembrane region of haemagglutinin (influenza virus), was knocked into 
the Cpa3 locus for mast cell-specific expression. In order to abrogate signalling 
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dependent receptor internalization, intracellular signalling chains of the hCD4 
molecule were excluded.  
To validate the model system for antibody-mediated mast cell depletion, we first 
demonstrated specific anti-hCD4 staining on mast cells from various tissues and no 
anti-hCD4 staining on circulating hematopoietic cells, with the exception of basophils. 
Differential intensity of hCD4 staining on mast cells from different tissues most likely 
reflects receptor cleavage by enzymatic treatment during tissue dissociation. 
Peritoneal mast cells harvested by peritoneal lavage display a 2-3 fold higher anti-
hCD4 mean fluorescence than mast cells isolated by enzymatic tissue digestion from 
skin. Accordingly, incubation of peritoneal mast cells with collagenase reduced hCD4 
staining intensity up to 10-fold. Gene expression data provided by the Immgen 
consortium indicate strong and highly similar levels of Cpa3 mRNA expression in 
different mast cell populations (Dwyer et al., 2016). Taken together, all mast cell 
populations from Cpa3hCD4 mice that we analysed in our study stained positive for 
hCD4, and most likely express this knock-in allele at similar cell surface levels, 
hence, the Cpa3hCD4 mouse a suitable model for establishing antibody-mediated mast 
cell depletion conditions. 
 
Previous studies have indicated that the antibody Fc-portion is paramount for the 
induction of specific effector functions. Main effector cells in ADCC are NK cells and 
phagocytic mononuclear cells, which are most efficiently activated by FcγRI and 
FcγRIV (Nimmerjahn and Ravetch, 2008). The antibody isotype with the highest 
affinity for these receptors is IgG2a (Nimmerjahn, 2005). We therefore chose 
TNX355, which is a mouse IgG2a monoclonal antibody recognizing human CD4. In 
our experiments, we compared two variants of TNX355, one with normal 
glycosylation and an afucosylated variant. Removal of the fucose from the Fc-
fragment of IgG2a was reported to further enhance the cytotoxicity (Nimmerjahn, 
2005).  
 
Single dose intravenous treatment with TNX355 resulted in a reduction of peritoneal 
mast cells but had no effect on stomach, skin, fat or tongue mast cells. Scholten and 
colleagues, who developed the Mcpt5-cre iDTR mouse strain, showed that repetitive 
diphtheria toxin injections were required for skin mast cell ablation in their model 
(Julia Scholten, 2009). When we subjected mice to repetitive doses of TNX355 we 
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observed a dose-dependent depletion of peritoneal and stomach mast cells. At the 
highest dose tested, peritoneal and stomach mast cells were fully ablated, however 
the connective tissue embedded skin, tongue and fat mast cells could not be 
depleted by ADCC. Unexpectedly, injection of the afucosylated TNX355 antibody did 
not further enhance ADCC-mediated mast cell ablation in our model. Of note, 
injection of normally glycosylated isotype control antibody induced CD45+ immune 
cell infiltration into the tongue, which was absent in the afucosylated isotype control 
antibody. These results suggest that either the fucose chain of normally glycosylated 
mAbs has an effect on the immune system, as has been described for other glycans, 
such as sialic acid in IVIG preparations, or that the normal glycosylated isotype 
antibody was contaminated with endotoxin and therefore elicited an immune 
response (Abès and Teillaud, 2010). 
We could not eliminate connective tissue mast cells. We therefore investigated 
whether antibodies can efficiently reach the tissue resident mast cells from the blood 
stream. Studies on antibody pharmacokinetics indicate diffusion along a 
concentration gradient as the major driver of mAb biodistribution in vivo (Tabrizi et 
al., 2009). Diffusion depends on the blood pressure, the capillary endothelium and 
the underlying basement membrane structure. In regard of the vessel structure, it has 
previously been reported that the vascular endothelium of the skin acts as a 
gatekeeper to proteins larger than 75 kDa, hence antibodies with sizes of more than 
150 kDa should not cross the vascular bed (Egawa et al., 2013). In contrast, we 
observed positive staining of all skin resident mast cells after intravenous injection of 
a low dose (100 µg) of Alexa 647-labelled TNX355. Mast cells that are in vicinity of 
blood vessels may extend protrusions into the blood vessels e.g. to ‘catch’ IgE from 
the circulation (Cheng et al., 2013). It may be possible for circulating TNX355 to bind 
to the protrusions of blood vessel-associated mast cells. However, when we 
analysed several mast cell compartments of these mice, not all of which may be 
associated with the endothelium, we found homogenous A647 label on all mast cells 
suggesting that the antibody broadly entered tissues. We conclude that the absence 
of antibodies in the tissues is not responsible for lack of depletion of hCD4+ mast 
cells. 
Efficient depletion of peritoneal mast cells by ADCC is most likely mediated by the 
large population of locally resident macrophages (15-30 times the number of mast 
cells), which can freely move around the serosal cavity (Davies et al., 2013). In the 
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skin, however, there are considerably lower number of macrophages (2-3 times the 
number of mast cells) and tight extracellular matrix of the connective tissue impairs 
free movement of cells (Tong et al., 2015). Thus, we propose that the lack of ADCC 
in skin, tongue and fat tissue may result from lack of effector cells and/or lack of 
functionality of the locally resident immune effector cells. 
 
One of our aims was also to investigate the safety of mAb-dependent mast cell 
ablation in vivo. Sudden loss of mast cells likely leads to release of mast cell 
granules (Scholten et al., 2009). Instantaneous and massive release of mast cell 
granules could induce anaphylactic shock and thus limit the applicability of such a 
mast cell-directed targeting approach. In the Mcpt5-cre iDTR mouse model mast cell 
ablation by apoptosis resulted in morbidity of a small proportion of mice. The authors 
were able to rescue these mice by co-administration of H1-antagonists, and thus 
concluded that mast cell released histamine caused the observed morbidity 
(Scholten et al., 2009). In our ADCC-based mast cell ablation experiments we did not 
observe morbidity, which may result from our less efficient mast cell depletion, yet it 
might also indicate that mast cell ablation by phagocytosis follows slower kinetics. 
4.5. Functional assessment of mast cell depletion 
With the TNX355 antibody in our Cpa3hCD4 mouse model it was possible to induce 
complete elimination of mast cells in the peritoneal cavity and stomach. While the 
antibody reached other tissue-resident mast cells (skin, tongue, fat, trachea), no 
depletion occurred in these compartments. We tested whether mast cell depletion in 
peritoneal cavity and stomach may already have an impact on passive systemic 
anaphylaxis. This is one of the few in vivo assays that is mast cell specific  
(Feyerabend et al., 2011; Wershil et al., 1987). In this assay, mice are passively 
sensitized by injection of antigen specific IgE. Challenge of mice with antigen results 
in crosslinking of the FcεRI-bound IgE on the surface of mast cells. The 
degranulation of sensitized mast cells results in systemic release of histamine, 
leukotrienes and prostaglandins leading to vascular leakage, reduced blood pressure 
and hypothermia (Ogawa and Grant, 2007). The latter are key readout parameter in 
this in vivo model of mast cell activation. While complete mast cell deficiency protects 
Cpa3Cre mice from IgE-mediated anaphylaxis (Feyerabend et al., 2011), partial 
TNX355-mediated ablation of peritoneal and stomach mast cells did not significantly 
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abolish the anaphylactic response, suggesting that mast cell activation in skin and 
other tissues is mainly responsible for the observed hypothermia.  
4.6. CD63 as physiological target for mast cell ablation 
The development of cell depleting biologicals is a relatively new field of treatment. 
For preclinical drug testing several different approaches have been used. We first 
aimed to evaluate the efficacy and safety of targeting physiological antigens that are 
conserved in mast cells across species. One of the molecules enriched in both 
mouse and human mast cells is CD63. We decided to use an anti-mouse CD63 
antibody as our first candidate for antibody-mediated mast cell depletion. Binding of 
antibodies to the surface of mast cells may result in mast cell activation with potential 
lethal consequences for the host. In that regard, CD63 appears to be a reasonable 
target as, in vivo studies with mAbs directed at CD63 could show that antibody 
binding to the surface of mast cells attenuates mast cell activation, however does not 
induce cell death (Kraft, 2005; Kraft et al., 2013). However, apart from activating 
mast cells, the binding to- and depletion of CD63+ non-mast cells may induce side 
effects. This, so called, on target toxicity poses a serious risk, especially since human 
CD63 surface cell surface expression is not entirely restricted to mast cells (Fig. 24) 
and mouse CD63 is highly expressed in the kidneys (Pols and Klumperman, 2009).  
In our hCD4 system, peritoneal mast cells were safely and efficiently targeted 
presumably by Fc-mediated effector mechanisms, however, when we treated mice 
with anti-mouse CD63 antibodies there was no mast cell depletion. Given that anti-
hCD4 of the same concentration and isotype was able to reduce the number of mast 
cells profoundly, we reasoned that intrinsic properties of CD63 were responsible for 
the lack of depletion. For efficient Fc-mediated effector engagement to occur, stable 
cell surface exposition of the target and antibody is required (Trail, 2013). When we 
tested hCD63 receptor internalization after antibody binding on human skin mast 
cells in vitro, we observed rapid internalization of anti-hCD63. These data suggest 
that antibody internalization limits efficacy of anti-mouse CD63 targeting in vivo. 
While internalization limits the efficacy of an ADCC-mediated mast cell depletion 
mechanism, it opens the possibility for antibody-drug-conjugate mediated mast cell 
depletion. In contrast to ADCC, ADC-cytotoxicity relies on target:toxin complex 
internalisation to be effective. Various antibody-drug conjugates have been used 
experimentally and in the clinics. Most molecules currently produced for the clinics 
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are fusion proteins of pseudomonas/diphtheria toxin and an antibody targeting moiety 
(Tabrizi et al., 2009; Trail, 2013). The production and purification of such targeted 
toxins is costly and only worthwhile once a suitable target is established. In order to 
circumvent the production of our own antibody-drug conjugates we chose to use the 
commercially available strepatividin-saporin conjugate. Saporin is a ricin derivate, 
devoid of the membrane translocation domain, and thus, by itself not toxic (Stirpe et 
al., 1992). Addition of this conjugate to biotinylated antibodies generates potent 
antibody drug conjugates, which have been used to target a variety of cells in vitro 
and in vivo (Cao et al., 2016; Ehrlich et al., 2014; Palchaudhuri et al., 2016).  
The hCD4 molecule that was introduced into the Cpa3 locus in our Cpa3hCD4 model 
was designed for persistent cell surface exposure for enhanced ADCC. For that 
reason it is unsuitable for ADC-mediated mast cell ablation that depends on 
target:toxin internalisation. To establish an ADC-mediated mast cell depletion, we 
chose the rapidly internalising physiological mast cell antigen CD63. Treatment of 
mouse peritoneal and bone-marrow derived mast cells with CD63-SAP resulted in 
specific dose dependent cell death in vitro. 
In contrast to the encouraging results obtained in vitro, CD63-SAP did not induce 
mast cell depletion in vivo. 2 out of 3 mice displayed serious side effects, including 
weight loss, hunchback and impaired mobility. SAP-treated control animals did not 
display signs of disease, suggesting that the observed effect was due to binding of 
CD63 to its physiological target. Due to lack of mast cell ablation efficacy we did not 
further investigate the cause of the observed toxicities. However, we suspect that on-
target toxicity, most likely, in the kidney contributed to the morbidity. Based on these 
results we conclude that systemic depletion of mast cells by anti-CD63 antibodies is 
not feasible. It might be possible to locally deplete tissue resident mast cells to 
circumvent systemic exposure of CD63-SAP or whether saporin might be used in 
combination with any of the other identified mast cell markers remains to be 
determined.  
4.7. Summary and outlook 
Even though mast cells have been discovered for over a century ago they are mostly 
known for their functions in IgE-mediated immediate hypersensitivity reactions, which 
in most cases contributes to pathology. To better understand the functions of mast 
Discussion 
 93 
cells we performed quantitative mass spectrometry-assisted proteomic profiling of 
primary mouse and human mast cells. This analysis confirmed the expression of 
several well-known mast cell specific proteases as well as revealed several proteins 
that have previously not been described in mast cells. Comparison of the mouse and 
human mast cell proteome revealed that core functions of mast cells, such as the 
generation of granules and histamine synthesis, are conserved between species, and 
might have been evolutionary maintained in mast cells for over 500 million years. 
Understanding the function of the mast cell specific proteins that we identified in our 
analysis will aid in deciphering new roles of the cells. 
Mast cells are major players in asthma and allergic disease and their absence does 
not appear to cause immunodeficiency. Hence, mast cell ablation may become 
possible in the future. Our experiments with Cpa3hCD4 mice provide proof of principle 
that mast cell depletion by antibodies is safe and feasible, as we were able to 
completely eradicate peritoneal and stomach mast cells in vivo without apparent 
adverse effects. In most human allergic diseases, however, tissue-embedded mast 
cells, such as skin- or lung mast cells, are involved. These compartments appeared 
to be protected from antibody-dependent cell-mediated cytotoxicity, at least as far as 
we could test this in our model system.  
In contrast to the generally accepted dogma, we could exclude that limited antibody 
availability in tissues is causative for the lack of tissue cell depletion. Instead, we 
argue that limited availability and activity of immune effector mechanisms results in 
the observed lack of anti-mast cell activity of the anti-hCD4 antibody. To bypass this 
immune-cell dependent limitation we explored the possibility of antibody drug 
conjugate-mediated mast cell depletion. Our proteomic profiling experiment revealed 
several physiologically expressed mast cell specific cell surface antigens that may 
allow for antibody-dependen cell ablation. One of these receptors is CD63, which we 
investigated as a target for saporin-coupled anti-CD63 antibodies. Incubation of mast 
cells with an anti-CD63 immunotoxin resulted in the efficient depletion of mast cell in 
vitro. Treatment of mice with this drug, however, resulted in severe side effects 
without mast cell depleting activity. From these experiments we conclude that CD63 
may be unsuitable as a target for systemic delivery of anti-mast cell ADCs, however, 
local application of CD63 targeted immunotoxins, e.g. to the skin, might circumvent 
systemic side effects. In future studies aim at investigating such local application of 
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mast cell depleting agents, as well as use our newly identified physiological 
candidate receptors to deplete mast cells in vivo.  
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Figure S1: Flow cytometry-gating strategy for mouse peritoneal cells and splenocytes 
a) Gating of peritoneal cells to identify mast cells (live CD117+), T cells (live CD3+), B cells (live CD19+) and macrophages (live 
F4/80+ CD3- CD19-) by flow cytometry. b) Gating of spleen cells to identify T cells (live CD3+), B cells (live CD19+), basophils (live 
CD49b+ IgE+), eosinophils (live SSChi Siglec-F+), and neutrophils (live CD11b+ Gr-1+). 
  
 
Figure S2: Flow cytometry of mouse mast cell enriched antigens 
Populations from S1 were tested for immunoreactivity against the mast cell enriched antigens FcεRI, CD147, CD317, CD34, CD49b, 
CD171, CD107a, P2rx7, and ß7-integrin by flow cytometry. Shown is the mean of the staining index ± SEM of three animals per group. 
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Figure S3: Flow cytometry-gating strategy for human PBMC 
Gating of PBMC to identify neutrophils (SSCint live CD16+), eosinophils (SSChi high CD193+), monocytes (live CD14+), pDCs (live 
CD123+ FcεRIlow), basophils (live CD123+ FcεRIhi), CD4 T cells (live CD3+ CD4+, and CD8 T cells (live CD3+). 
 
 
 
Figure S4: Flow cytometry of human mast cell enriched antigens 
Populations from S3 were tested for immunoreactivity against the mast cell enriched antigens SIGLEC8, FcεRI, CD26, CD44, CD51, 
CD59 and CD54 by flow cytometry. Shown is the mean staining index ± SEM of 1-6 samples per group. 
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